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1 Abstract 
Acute leukemias (AL) are hematological malignancies with poor outcomes, and disease relapse 
represents a major challenge. Treatment resistant cells might persist for prolonged periods of 
time, might start proliferation and give rise to relapse. Novel treatment options are urgently 
needed to eradicate resistant cells and to prevent relapse in order to improve the prognosis and 
cure rate of AL patients. The aim of the present work was to identify and characterize the 
subpopulation of relapse-inducing cells in AL.  
Towards this aim, a unique method was used which had been established shortly before in the 
hosting lab. Here, primary AL cells from patients are propagated in immunodeficient mice as 
patient-derived xenografts (PDX) cells. Using genetic engineering of PDX cells and a two-step 
enrichment protocol targeting the transgenes, minor numbers of PDX cells can be isolated from 
mouse bone marrow to near purity in an unbiased way. Using the proliferation-sensitive dye 5-
(6)-Carboxyfluorescein-Succinimidyl Ester (CFSE) in mice, first hints had been generated that 
cells might exist in acute lymphoblastic leukemia (ALL) which reveal long term dormancy.  
In this work, the present method was optimized and transferred to acute myeloid leukemia 
(AML). The study showed that 8 out of 8 tested ALL PDX samples and 8 out of 9 AML samples 
contained a rare subpopulation of long-term dormant cells indicating that long-term dormancy 
represents a frequent feature in PDX AL. Upon systemic treatment of mice with 
chemotherapeutic drugs, proliferating cells showed marked sensitivity, while long-term 
dormant cells remained resistant. Long-term dormant cells contained cancer stem cells as they 
were able to initiate leukemia in next recipient mice. 
Thus, most patients' AL contains a rare subpopulation of dormant, treatment resistant cells with 
leukemia initiating properties which might represent a surrogate for relapse-inducing cells. Re-
transplantation experiments indicated that dormant cells started proliferating in next recipient 
mice, while proliferating cells converted into long-term dormant cells indicating a major 
functional cell plasticity.  
In conclusion, a rare cell population was identified that might serve as suitable surrogate to 
develop novel therapies against relapse in AL, targeting the challenging subpopulation of 
dormant, drug resistant, leukemia initiating cells. The transient nature of dormancy suggests 
that AL patients might profit from treatment strategies which release dormant, treatment 
resistant cells from their microenvironment in order to sensitize them towards treatment. 
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2 Introduction 
2.1 Acute Leukemias (AL) 
Acute leukemias (AL) belong to the ten most common cancers in the United States and Europe 
(Ferlay et al., 2013; Siegel et al., 2016). AL are hematologic malignancies with a rapid increase 
of immature blood cells. The accumulation of malignant, non-functional cells leads to an 
interference with healthy blood cells, and finally to bone marrow failure. Depending on the 
surface markers expressed on the tumor cells, AL is distinguished into two subtypes: acute 
myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (Esparza and Sakamoto, 
2005; Estey, 2014).  
2.1.1 Acute myeloid leukemia (AML) 
AML is the most common leukemia in adults. In the US there are around 20,000 new patients 
per year and around 10,000 patients die from AML each year (Siegel et al., 2016). The incidence 
rises with an increase in age; patients older than 65 years are over 10 times more frequently 
effected than patients younger than 65. The median age of patients diagnosed with AML is 
around 70 years (De Kouchkovsky and Abdul-Hay, 2016; Estey and Dohner, 2006). 
Environmental influences like ionizing radiation are known to have an influence on the 
development of AML. 10-15 % of AML patients underwent a previous cytotoxic 
chemotherapy, and cigarette smokers develop 1.2-2.3 times more often AML than non-smokers 
due to benzene exposure (Estey and Dohner, 2006). AML is a heterogeneous disease with many 
different subtypes due to different genetic mutations, epigenetic aberrations, and downstream 
abnormalities. More than 97 % of AML tumors reveal known genetic mutations. In addition, 
around 55 % of AML cases show cytogenetic abnormalities, like translocations, inversions, and 
chromosomal imbalances, or even complex karyotypes (Estey and Dohner, 2006).  
The ancient French-American-British (FAB) classification system from 1976 uses 
cytomorphological and cytochemical characteristics of the myeloid blasts to group AML into 
eight AML subtypes. The World Health Organization released 2001 a new classification, which 
was revised 2008 and 2016 to incorporate genetic information, morphology, 
immunophenotype, and clinical presentation. Here, six AML subtypes are distinguished (De 
Kouchkovsky and Abdul-Hay, 2016; Estey and Dohner, 2006). The European Leukemia NET 
(ELN) classification incorporates cytogenetics and molecular genetic data, especially mutations 
in the NPM1, FLT3, and CEBPA genes, to define four risk groups. According to their 
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prognosis, the different groups are called favorable, intermediate-1, intermediate-2, and adverse 
which have in total 13 subsets (Estey, 2014; Roboz, 2012).  
AML is diagnosed cytomorphologically by malignant blasts in bone marrow or peripheral 
blood of patients, and by positive testing of these cells for a myeloid origin by myeloperoxidase 
activity, or the presence of Auer rods (De Kouchkovsky and Abdul-Hay, 2016). Furthermore, 
myeloid blasts are identified immunophenotypically by the expression of typical myeloid 
surface markers, like CD33 and CD13 (Estey and Dohner, 2006; Estey, 2014). The 
accumulation of these malignant, undifferentiated myeloid blasts in the bone marrow leads to 
an interference with the normal hematological cells and eventually to bone marrow failure. In 
addition, myeloid blast can escape into the blood stream and spread to other organs of the body. 
Untreated, this cell accumulation leads to death within months (De Kouchkovsky and Abdul-
Hay, 2016; Estey and Dohner, 2006). All patients are immediately treated by standard therapy, 
often even before the risk group is determined, which has the best outcomes for patients with a 
favorable or intermediate prognosis and a low risk of treatment-related mortality. The standard 
regimen includes two phases. The first phase, induction therapy, aims to achieve complete 
remission, which is defined by less than 5 % blasts in the bone marrow. Here, an anthracycline, 
like idarubicin or daunorubicin is given for three days, and in parallel a continuous 
administration of cytarabine is given for seven days. This so-called 3+7 scheme is repeated one 
to four times until complete remission is reached (De Kouchkovsky and Abdul-Hay, 2016; 
Estey and Dohner, 2006). After induction therapy stops, many patients develop relapse (Thol 
et al., 2015). In order to prevent relapse, the second phase, the consolidation therapy, starts to 
achieve lasting remission. If patients seem to not tolerate the intensive chemotherapy or 
chemotherapy alone is not effective, another possibility is allogeneic stem cell transplantation. 
Furthermore, for patients with a poor prognosis or a high risk of treatment-related mortality, 
investigational therapy, as part of a clinical trial, is an option (De Kouchkovsky and Abdul-
Hay, 2016; Estey and Dohner, 2006). 
Despite optimized chemotherapy and supportive care, the outcome for patients with AML is 
still poor. The long-term overall survival of younger patients is around 40-50 %. For patients 
older than 65, many of which also show a poor performance status, the prognosis is even worse, 
70 % will die within one year (Estey, 2014; Roboz, 2012). 
Besides age and performance status, the most relevant prognostic factor for chemotherapy 
response and outcome are the cytogenetic and molecular findings at diagnosis. Additionally, 
patients who suffer from a therapy-related AML or from AML after myelodysplastic syndrome 
are more resistant to chemotherapy and have a worse outcome. Therapeutic failure occurs due 
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to treatment resistance or due to treatment-related mortality. Treatment resistance is defined if 
complete remission cannot be achieved or maintained or if a relapse cannot be prevented or 
treated. Treatment-related mortality counts for patients who died from the adverse-effects of 
treatment (Estey, 2014). Prognostic markers for treatment-related mortality in patients are age 
and performance status at diagnosis, as well as platelet count, serum albumin, bilirubin and 
creatinine (De Kouchkovsky and Abdul-Hay, 2016; Estey and Dohner, 2006). 
In summary, AML is associated with an overall poor prognosis, especially for elderly patients, 
certain adverse subgroups and upon relapse. Genome sequencing data revealed AML as a very 
heterogeneous disease regarding mutations and cytogenetic abnormalities, which are a reason 
for diverse treatment outcomes. As the main treatment still consists of cytotoxic chemotherapy, 
an urgent need for new treatment strategies, like targeted therapies, exists (Estey and Dohner, 
2006). For the understanding of this complex biology, preclinical models are needed to finally 
develop new therapy strategies for a better prognosis of AML patients and to prevent AML 
relapse (Guzman and Allan, 2014).  
2.1.2 Acute lymphoblastic leukemia (ALL) 
ALL is the most common type of cancer in children. In the US are around 6,500 new cases per 
year (Siegel et al., 2016), hereof 60 % are persons younger than 20 years (Dores et al., 2012). 
The peak of incidence lies between the age of two and five (Hunger and Mullighan, 2015; Pui 
et al., 2008). However, also adults can develop the disease, but the incidence in adults is very 
low (Inaba et al., 2013; Pui et al., 2008). 
Some genetic factors, like Down’s syndrome, Blooms syndrome, ataxia-telangiectasia and 
Nijmegen breakage syndrome, are known to be associated with and leading to an increased risk 
of ALL (Hunger and Mullighan, 2015; Pui et al., 2008). In addition, some genetic alterations 
are associated with an increased risk for ALL or with a specific subtype of ALL. These include 
polymorphic variants in genes like ARID5B, CDKN2A, CEBPE, GATA3 and IKZF1. 
Environmental exposures like radiation, some chemicals, and exposure to electromagnetic 
fields only have little influence on the development of ALL (Hunger and Mullighan, 2015; 
Inaba et al., 2013). In most patients, the first oncogenic mutation appears in utero and before 
birth (Schiffman, 2016). 
The ancient French-American-British (FAB) classification divided ALL into three different 
subgroups by their morphological characterization. In 1997, and revised in 2008, the World 
Health organization combined morphological and cytogenetic criteria to divide ALL into three 
subtypes. The three main subtypes are mature B-cell, B-cell precursor (BCP-ALL) and T-cell 
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leukemia and have therapeutic implications. These subtypes can be further classified according 
to their specific genetic alterations (Pui et al., 2008; Terwilliger and Abdul-Hay, 2017). Besides 
karyotypic abnormalities, like aneuploidy or translocations, nowadays genome-wide analysis 
allows the genetic classification of all cases by the identification of genetic alterations, but is 
not yet used in clinical routine. Genes altered in ALL are often associated with hematopoietic 
differentiation, signaling or proliferation, and epigenetic regulation (Pui et al., 2012; Pui and 
Evans, 2013). A recently identified high risk immature subtype is early T-cell precursor (ETP) 
ALL, which is defined by specific immunological markers, characteristic gene expression 
profile, a mutational spectrum related to AML mutations, and transcriptional profile close to 
hematopoietic stem cells and granulocyte-macrophage precursors. These are hints for a stem 
cell disease of this subtype (Zhang et al., 2012). 
ALL is diagnosed by morphological and immunophenotyping examinations of peripheral blood 
or bone marrow aspirates (Inaba et al., 2013; Pui et al., 2008). The further discrimination 
between T-cell, mature B-cell, BCP ALL, and ETP-ALL is subsequently important for 
therapeutic procedures (Pui et al., 2008). To identify chromosomal abnormalities like hyper- 
and hypodiploidies and leukemia-specific gene rearrangements, translocation-specific RT-PCR 
and fluorescence in-situ hybridization are used. Flow cytometry is performed to identify the 
cell linage and CRLF2 overexpression. Genome-wide analyses are not used in clinical routine 
yet, but have prognostic and therapeutic implications, too. As a consequence of these diagnostic 
measures combined with clinical data, children are stratified in several risk groups which 
receive different intensity of treatment. Tumor-specific molecular markers are further used to 
quantify tumor load repetitively in each patient in order to evaluate treatment effects and to 
recognize any putative tumor re-growth early (Inaba et al., 2013; Pui et al., 2008). Without 
treatment patients die of the disease. The malignant and undifferentiated lymphoid cells 
accumulate in the bone marrow, lead to interference with healthy hematopoietic cells and 
eventually to bone marrow failure. Malignant cells can invade into the blood stream and affect 
other organs of the body (Terwilliger and Abdul-Hay, 2017). 
Treatment of all subtypes is divided into three phases: remission-induction therapy, 
consolidation therapy and maintenance therapy. Induction therapy, lasting for four to six weeks, 
includes a glucocorticoid, vincristine, and asparaginase or anthracycline. Standard risk children 
receive a combination of three chemotherapeutics, whereas high risk, very high risk, and adult 
patients receive a combination of four or more different chemotherapeutics. Patients with 
BCR-ABL1 translocation benefit from tyrosine-kinase inhibitors, like Imatinib (Inaba et al., 
2013; Pui et al., 2008). 
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Morphologic remission is defined by less than 1 % blasts in bone marrow; morphological 
remission is obtained in 96-99 % of children and in 78-92 % of adult patients (Inaba et al., 2013; 
Pui and Evans, 2006; Pui et al., 2008). 
The consequent 20-30 weeks of consolidation therapy are used to target residual leukemic cells. 
Here, high-doses of methotrexate with mercaptopurine, frequent applications of vincristine and 
corticosteroid and repetitive applications of asparaginase, as well as drugs from induction 
therapy are used (Inaba et al., 2013; Pui et al., 2008). 
The treatment phase of maintenance therapy lasts for around two years. This therapy phase shall 
prevent relapse and increase event-free and overall survival in patients. Here, daily 
mercaptopurine and weekly methotrexate is given with or without applications of vincristine 
and dexamethasone (Inaba et al., 2013; Pui et al., 2008). 
For patients who did not response to initial treatment or have a high-risk ALL, like BCR/ABL-
positive ALL, allogeneic hematopoietic stem cell transplantation or investigational therapy, as 
part of a clinical trial, are options (Inaba et al., 2013; Pui et al., 2008). 
During the last decades, treatment optimization, increase in supportive care and risk assessment 
to use the best treatment strategy have been resulted in improvements, especially for children, 
from a former deadly disease in the 1950s to 5-year survival rates above 90 % (Inaba et al., 
2013; Siegel et al., 2016). But survival rates for adults and infants remains little satisfactory 
with around 40 % survival rates for young adults and less than 10 % for adults older than 60 
years (Dördelmann et al., 1999; Goldstone et al., 2008). The survival rates of BCR/ABL-
positive ALL have improved through new treatment strategies including tyrosine kinase 
inhibitors from initial 10 % to around 40-60 % (Leoni and Biondi, 2015). Most ALL patients 
die from relapse and relapse occurs in 15-20 % of children and in 40-50 % of adult patients. 
The prognosis of relapsed patients is poor; in adults only less than 10 %, and in children 40-
50 % can be cured, due to increased treatment resistance of relapsed ALL (Gokbuget et al., 
2012a; Locatelli et al., 2013). 
There are several factors besides the subtype and molecular alterations that are of prognostic 
relevance in ALL: 
One is the age at diagnosis of the initial. Children between the age of 1 and 9 have better 
outcome than infants, adolescents, or adults (Hilden et al., 2006). Younger adults have a better 
prognosis than older ones. 
Another prognostic factor is the race, with black and Hispanic patients have worse outcome 
compared to white people treated exactly the same (Inaba et al., 2013; Pui et al., 2008). 
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Furthermore, an increase in leucocyte count above 50x109/L is associated with poorer outcome 
(Inaba et al., 2013; Pui et al., 2008).  
The most important prognostic factor for children and adults and even for patients with low-
risk disease at initial diagnosis is the determination of the minimal residual disease (MRD) 
levels during the induction therapy (Inaba et al., 2013). To determine and quantify these drug 
resistant MRD cells, morphological methods are recently replaced by the more sensitive 
methods of flow-cytometry and PCR amplifications. The advantage of PCR is the high 
sensitivity; here MRD levels around 0.001 % can be measured. With flow-cytometry MRD 
levels around 0.01 % can be determined, but this method is fast, less expensive and is applicable 
to a broad range of patients, allowing a fast treatment adjustment (Inaba et al., 2013). 
Measurement of MRD levels three months after diagnosis is associated with following risk 
groups for outcome: No detectable MRD level is associated with low risk, MRD levels between 
10-4 and 5x10-4 are associated with medium risk, and MRD levels above 5x10-4 are associated 
with high risk (van Dongen et al., 2015). 
Taken together, although most ALL patients have a good prognosis, as survival rates are high, 
the prognosis for infants and adults is still poor due to frequent ALL relapse. Therefore, new 
treatment options are needed which target residual, treatment resistant cells and prevent ALL 
relapse. 
2.2 Biology of AL cells 
In order to prevent AL relapse by new treatment strategies, a deep knowledge of the biology of 
AL cells is necessary. The following chapter will give an overview about the most important 
adverse characteristics of AL cells, which make it difficult to treat and cure patients with AL 
and to prevent disease relapse. 
2.2.1 Drug resistance 
Drug resistant cells represent an important reason for treatment failure in AL. These cells are a 
major threat for ALL and AML patients as they survive initial chemotherapy, might persist in 
the patient at MRD levels, and are able to induce a tumor relapse with poor prognosis (Blatter 
and Rottenberg, 2015; Gokbuget et al., 2012b; Pettit et al., 2016). For example in childhood 
ALL resistance towards glucocorticoids is a major problem. ALL patients which are not 
responding toward glucocorticoid chemotherapy have in general a worse prognosis than 
patients with a response. The underlying mechanisms for resistance remain at least on part 
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elusive (Inaba and Pui, 2010). In general, despite their major clinical importance, the 
mechanisms leading to drug resistance and the basic biologic conditions of relapse are still 
poorly understood. For instance it is not known whether relapse-inducing cells exist before 
treatment or whether they develop due to treatment and it is unclear if constant or transient 
features determine relapse-inducing cells (Kunz et al., 2015). In addition, gained genetic 
alterations might increase the drug resistance of rare subclones. And even chemotherapy itself 
might pressure and select for the most aggressive and drug resistant cell clones. Besides drug 
resistant cells might be induced by a protective surrounding microenvironment, so that 
chemotherapeutics cannot reach these cells, or the microenvironmental conditions exert an 
impaired effect on these agents (Ishikawa et al., 2007).  
Furthermore, drug resistance is closely associated with dormancy of cancer cells as 
conventional chemotherapy mainly interferes with cell cycle dependent processes which are 
not active in dormant cells (Clevers, 2011; Zhou et al., 2009).  
Taken together the eradication of drug resistant cells is a major goal for new treatment 
strategies, as tumor relapse caused by drug resistant cells is associated with dismal prognosis.  
2.2.2 Dormancy 
In many tumors entities, relapse occurs after initial successful treatment and is associated with 
poor prognosis. Reasons for relapse are tumor cells that survived treatment and persist for 
longtime, sometimes even decades, as minimal residual disease (MRD) cells. One cause for 
their resistance and longtime persistence might be their dormant state (Aguirre-Ghiso, 2007; 
Essers and Trumpp, 2010; Schillert et al., 2013). As conventional chemotherapy is cell cycle 
dependent and mechanisms required for cell proliferation are not active in dormant cells, 
dormancy might be a reason for resistance to chemotherapy (Clevers, 2011; Zhou et al., 2009).  
Many different adult stem cells contain dormant cells and as cancer stem cells (CSC) share 
various characteristics of these cells, dormancy might be an important characteristic within 
CSC, too (Orford and Scadden, 2008; Schillert et al., 2013). 
As mouse hematopoietic stem cells (HSC) represent the stem cells best characterized, many 
studies identified the existence of dormant cells within this population (Cheshier et al., 1999; 
Passegue et al., 2005; van der Wath et al., 2009; Wilson et al., 2008; Wilson et al., 2007; 
Yoshihara et al., 2007). In contrast, only few studies investigated dormancy in cancer cells so 
far, as (I) small subpopulations are difficult to identify due to detection limits, (II) lack of 
adequate markers to identify dormant tumor cells, and (III) lack of adequate model systems 
(Schillert et al., 2013). Some studies connected dormancy of CSC in a specific tissue with 
Introduction  9 
 
 
 
increased drug resistance. For ovarian tumor cells, it has been shown that the CD24+ stem cell 
population proliferates slower, is more tumorigenic and more resistant to cisplatin (Gao et al., 
2010). With the help of the proliferating dependent dye 5-(6)-Carboxyfluorescein-Succinimidyl 
Ester (CFSE), a subpopulation of dormant cells, which is more resistant to chemotherapy and 
is able to start proliferation, was detected in a xenograft model of human primary breast cancer 
cells (Moore et al., 2012).  
Even in BCR/ABL positive chronic myeloid leukemia, quiescent and Imatinib mesylate 
resistant stem cells have been identified (Essers and Trumpp, 2010). In addition, Guan and 
coworkers showed that most leukemia initiating cell (LIC) of primary AML cells were dormant, 
therefore mainly quiescent AML cells were able to induce a tumor in NOD/SCID mice (Guan 
et al., 2003). In a xenograft mouse model of AML, it has been shown that dormancy and 
chemotherapy resistance of CD34+CD38- human AML leukemia stem cell (LSC) are 
connected. Here AML LSC are quiescent, chemotherapy resistant, and enriched in the mouse 
bone marrow endosteal niche (Ishikawa et al., 2007; Saito et al., 2010a; Saito et al., 2010b). 
The bone marrow endosteal niche is defined as the region around the bone matrix with a 
distance of less than 100 µm to the closest bone matrix (Nombela-Arrieta et al., 2013). The 
niche itself is an elusive structure within the bone marrow microenvironment. Several cellular 
components, like osteoblastic, endothelial, and mesenchymal cell, have been identified to 
contribute to the niche, as well as the signaling by molecular cross-talk and soluble factors 
provided by these cellular components and the HSC (Kiel and Morrison, 2008; Wilson and 
Trumpp, 2006). 
Identifying dormant tumor cells in primary patients’ samples is rather challenging (Essers and 
Trumpp, 2010), but feasible with Ki-67 staining in certain ALL subtypes where an 
accumulation of non-proliferating cells after chemotherapy has been described (Lutz et al., 
2013). For these measurements, it remains unclear for how long dormancy persisted, as Ki-67 
staining gives a snapshot of a given moment, but fails to distinguish between long-term and 
short-term dormancy.  
Especially the localization and microenvironment of dormant hematopoietic and CSC are 
supposed to represent a cause for their dormancy (Ishikawa et al., 2007; Saito et al., 2010b; 
Zhou et al., 2009). Labeling with proliferation specific dyes enabled the localization of dormant 
HSC. These cells are mainly localized close to the bone surface, the endosteum (Arai et al., 
2004; Fleming et al., 2008; Wilson et al., 2008; Wilson et al., 2007). These sites are assumed 
to be specialized niches and are called the endosteal bone marrow niches, where several studies 
showed an enrichment of HSC (Wilson and Trumpp, 2006). In addition for AML stem cells the 
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localization to the endosteal bone marrow niche has also been shown (Ishikawa et al., 2007; 
Saito et al., 2010b; Zhou et al., 2009).  
Interaction and molecular crosstalk between niche and HSC, via cell-cell contacts and soluble 
factors, promote the localization and dormancy of HSC (Trumpp et al., 2010; Zhou et al., 2009). 
Several molecules have been identified which are associated with the regulation and activity of 
the bone marrow niche (Wilson 2006). 
One approach to overcome chemotherapy resistance of CSC is to overcome their dormancy. 
Dormant HSC can be activated and start to proliferate after treatment with granulocyte colony-
stimulating factor, interferon-α or arsenic trioxide. This activation sensitizes them toward 
chemotherapy treatment (Trumpp et al., 2010). Therefore the same has been proposed to 
overcome the dormancy and thus the resistance of LSC (Trumpp et al., 2010). 
In an AML xenotransplantation model, treatment with the cytokine G-CSF induced 
proliferation of former dormant LSC; subsequent treatment with the chemotherapeutic drug 
cytarabine induced a decrease of LIC frequency and a longer survival of mice (Saito et al., 
2010b).  
In summary, the subpopulation of dormant cells represents a major challenge in the treatment 
of cancer patients, and reversing their dormancy represents an important goal to overcome drug 
resistance, to prevent relapse and to cure cancer patients. New treatment strategies should aim 
at targeting dormant tumor cells by bringing them back into proliferation (Essers and Trumpp, 
2010; Saito et al., 2010b; Trumpp et al., 2010).  
2.2.3 Stemness 
In normal hematopoiesis, cells differentiate in several steps as a hierarchically organized 
differentiation tree from immature stem- and progenitor cells into specialized mature cells. 
Similarities between leukemia development and normal hematopoiesis led to the concept of 
cancer stem cells (CSC). The subpopulation of CSC differs from the bulk of tumor cells, as 
they represent a biologically distinct subpopulation, in AML with specific surface markers. 
CSC bear self-renewal properties, are responsible for tumor maintenance and relapse and they 
give rise to all tumor cells (Bonnet and Dick, 1997; Schillert et al., 2013; Visvader and 
Lindeman, 2008). CSC features are identical to those from adult stem cells. However, CSC 
might originate from more mature cells besides adult stem cells (Jordan et al., 2006). 
The gold-standard method to prove the existence of CSC in a certain tumor sample is 
xenotransplantation into immunodeficient mice, as CSC are defined by and unique in their 
potential to initiate a new tumor. Due to this functional phenotype, CSC are also called tumor 
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initiating cells. In literature, both terms are used identically, without distinction and with a 
certain transition between both terms (Bansal and Banerjee, 2009; Zhou et al., 2009). In 
leukemia, the term leukemia initiating cell (LIC) is frequently used, but also replaced by the 
term leukemia stem cell (LSC) (Matsushita et al., 2014).  
A CSC hierarchy has first been described in AML (Bonnet and Dick, 1997) and was also found 
in numerous solid tumors like breast cancer (Al-Hajj et al., 2003), pancreatic cancer (Hermann 
et al., 2007), and colorectal cancer (O'Brien et al., 2007).  
Many studies exist on LSC in AML, which makes them the best characterized CSC between all 
different tumor entities (Pollyea et al., 2014; Wang and Dick, 2005). LSC are capable to give 
rise to identical daughter cells and to more differentiated cells, and can be identified by their 
immunophenotype (Lapidot et al., 1994; Pollyea et al., 2014). Thus LSC share many 
characteristics of hematopoietic stem cells (HSC) (Bhatia et al., 1997; Guenechea et al., 2001). 
First studies identified LSC as negative for the expression of lineage markers (lin-), positive for 
CD34 (CD34+), and negative for CD38 (CD38-) (Bhatia et al., 1997; Bonnet and Dick, 1997; 
Reya et al., 2001). But recent studies showed that the phenotype of LSC is even more complex, 
with different expression of various markers appearing in individual patients or as a result of 
disease progression (Eppert et al., 2011; Sarry et al., 2011). In addition, it is proposed that LSC 
are mainly localized in specialized bone marrow niches, like it has been demonstrated for HSC 
(Ishikawa et al., 2007; Saito et al., 2010b; Wilson and Trumpp, 2006). These niches are 
necessary for the function of HSC, as they regulate the maintenance, self-renewal and 
differentiation of HSC.  
Only a small frequency of all AML tumor cells are LSC (Bonnet, 2008; Bonnet and Dick, 
1997). LSC is an operational term, as these cells sustain AML (Dick, 2008; Reya et al., 2001; 
Tan et al., 2006) and have been characterized by features like self-renewal, dormancy and 
treatment resistance. Therefore they are a clinically highly relevant subpopulation of 
challenging cells (Aguirre-Ghiso, 2007; Essers and Trumpp, 2010). These features are 
interdependent as, e.g., drug resistance might be a consequence of dormancy and temporary 
dormancy might represent a prerequisite for being a stem cell. If these features coexist in a 
given tumor cell, this cell is putatively able to induce relapse. In AML, it is difficult to eradicate 
LSC with standard chemotherapy as they have different characteristics compared to the bulk of 
tumor cells. Thus, LSC survive chemotherapy and might be responsible for tumor relapse 
(Schillert et al., 2013).  
In contrast, in ALL, a defined stem cell hierarchy has not yet been identified and phenotypic 
markers are unable to characterize the population of stem cells or predict self-renewal potential 
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(Kong et al., 2008; le Viseur et al., 2008). Many ALL cells display CSC properties and initiate 
leukemia in mice (Morisot et al., 2010; Rehe et al., 2013). Therefore, stemness seems to be an 
insufficient characteristic to describe the subpopulation of relapse-inducing cells in ALL. Since 
leukemia initiating potential is a feature of nearly every single cell in samples from ALL 
patients, ALL might even be functionally homogeneous regarding stemness. Nevertheless, ALL 
behaves like a non-homogeneous disease regarding additional characteristics; seminal studies 
revealed a clear genetic heterogeneity in ALL (Anderson et al., 2011; Mullighan, 2013); and 
the existence of MRD after treatment argues in favor of functional heterogeneity in ALL from 
a clinical point of view. 
In summary, many tumor entities, including AML contain a rare subpopulation of CSC which 
challenges tumor treatment, as cells differ from the bulk of tumor cells and often show treatment 
resistance. As these cells are able to induce a new tumor, relapse might occur due to the survival 
of only a few CSC. Even in ALL, where almost all cells seem to have tumor inducing potential, 
functionally heterogeneous subpopulations seem to exist, relapse occurs in many patients after 
initially successful treatment. For a final eradiation of the tumor, it is important to eradicate 
CSC (Wang, 2007). 
2.2.4 Intra-tumor heterogeneity 
The subpopulations within a tumor might differ regarding genetic, epigenetic and functional 
properties. The existence of MRD cells after treatment is a hallmark for the intra-tumor 
heterogeneity. Subpopulations with a survival benefit such as drug resistance or adverse 
genotype persist and represent a major problem for the cure of patients (Burrell et al., 2013; 
Marusyk et al., 2012; Metzeler and Herold, 2016).  
Recent developments in genomic profiling through sequencing technologies have revealed 
extensive genetic diversity between different tumors types, between the same tumor types from 
different patients, and even within the tumor cells of one patient (Burrell et al., 2013; Greaves 
and Maley, 2012). Here, individual mutations or chromosomal aberrations define different 
subclones. These subclones within one tumor are related to each other in a complex clonal 
architecture (Anderson et al., 2011; Greaves and Maley, 2012). By sequencing or multiplex 
fluorescence in situ hybridization, this complex subclonal architecture can be followed up and 
thus give an insight into the cancer evolution. Thereby the amount of alteration, the types of 
genetic alterations, and the shared mutations between different clones expose the relationship 
within the different clones (Ding et al., 2012; Greaves and Maley, 2012). This diversity can be 
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seen in many tumor entities, including ALL, where an evolution with many branches has been 
detected (Burrell et al., 2013; Mullighan, 2013).  
The development of the different cancer clones is considered as a Darwinian evolutionary 
process, meaning that the subclonal architecture develops during time. Selective pressure forms 
the different variants resulting in diverse functional characteristics for the individual clones 
(Ding et al., 2012).  
The main reason for the different variants is genetic instability, with an increased mutation rate 
which leads to the genetic heterogeneity. This genetic diversity forms the evolution of the 
cancer genome and is one reason for the phenotypic variations of the different subclones 
(Burrell et al., 2013). As most tumors show a kind of genomic instability, this seems to have a 
benefit for the tumor evolution. Normally the replication of the genome occurs with high 
precision, as monitoring and repair mechanisms only lead to a low mutation rate and failures in 
chromosome segregation are rare. But errors in the mechanisms that maintain genome integrity 
or the exposure to exogenous mutagens lead to an increase in the mutation rate (Burrell et al., 
2013). Different genomic instabilities lead to different genetic alterations, such as increased 
point mutations, small insertions and deletions, chromosomal rearrangements, and different 
chromosome numbers (Burrell et al., 2013).  
A reason for selective pressure during cancer evolution might be chemotherapy, as it selects for 
clones with drug resistance which here have a survival advantages (Greaves and Maley, 2012). 
In addition chemotherapy itself can induce new mutations and thereby has a direct influence on 
the evolutionary process (Burrell et al., 2013; Greaves and Maley, 2012). 
Often clonal evolution becomes noticeable when former effective treatment becomes later 
inefficient or is inefficient at relapse. This phenotypic evolution towards more aggressive clones 
can be explained by genotypic changes in the main tumor. These changes might result from 
additionally gained mutations, which lead to drug resistance or from former minor subclones 
with resistance, which than outcompete the other clones (Burrell et al., 2013; Marusyk et al., 
2012). This phenomenon has also been detected in AL. In AML and ALL the clonal 
development from diagnosis and the corresponding relapse samples has been studied. Here, it 
has been shown that the clonal composition in the relapse samples differs from the 
corresponding one at diagnosis, suggesting a clonal evolution process from diagnosis to relapse. 
The clones found in the relapse sample had a survival advantage, which might be because of 
additionally gained mutations responsible for drug resistance (Anderson et al., 2011; Ding et 
al., 2012; Mullighan, 2013). In the majority of cases, the clones found in the relapse samples 
could be related to the clones at diagnosis. In only 6 % of the cases, the relapse was genetically 
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not related to the subclones at diagnosis. Often the major relapse clone was already present at 
diagnosis as a minor subclone. In general, at relapse more alterations were detected, which 
might be because of the mutagenic chemotherapy or because of spontaneous mutations which 
lead to a survival benefit. In addition certain pathways were often altered in relapse samples 
suggesting a survival benefit for these mutations.  
In general, changes in the genotype of subclones are often associated with changes in the 
functional phenotype, like the patients’ prognosis or response to therapy. But phenotypic 
heterogeneity is not always generated through genetic diversity, furthermore stochastic events 
in gene expression or protein stability, microenvironmental differences, and epigenetic 
alterations also have an influence on the functional phenotype of subclones (Burrell et al., 
2013).  
Especially epigenetic heterogeneity has been shown in recent studies to account for differences 
of genetically identical subclones. Gene expression can be influenced by different DNA 
methylation patterns at gene promoters, which might then influence the functional phenotype 
like proliferation or drug sensitivity (Burrell et al., 2013).  
Some leukemia subtypes have a distinct epigenetic pattern such as an increased promoter 
methylation, which directly influences the corresponding gene expression levels. In AML and 
ALL several genes have been identified which are abnormally methylated (De Kouchkovsky 
and Abdul-Hay, 2016; Mullighan, 2013). But these findings also opened new perspectives for 
individual epigenetic treatment strategies. For leukemia the first epigenetic drugs, the DNA 
methyltransferase inhibitors 5-azacitidine and 5-aza-2′-deoxyazacytidine, are already in clinical 
use (Sato et al., 2017). 
Taken together the intra- tumor heterogeneity of AL, which involves different genetic, 
epigenetic, and functional subpopulations, provides a survival benefit for the tumor during 
chemotherapy. The cancer evolution and the related clonal heterogeneity are an important 
element for relapse. Therefore an effective treatment is challenging, as it should target all 
different subclones, but could also exert selective pressure which might lead to new mutations. 
Novel treatment strategies are urgently needed to target all subpopulation in order to prevent 
relapse. 
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2.3 In vivo models for AL 
As studies on the complex biology of AL cells cannot be performed directly in patients, suitable 
model systems have to be used. These model systems should mimic the situation in the patient 
in the best possible manner.  
Primary AL cells have restrictions as they do not grow in vitro, disabling their amplification. 
Primary cell material is limited, especially in children, and often not enough material can be 
isolated for a single experiment and experiments cannot be reproduced. Furthermore, AL cell 
lines are not a suitable model for complex studies because they display continuous proliferation, 
clearly discriminating them from relapse-inducing cells. In addition, cell lines changed clonal 
composition during the process of immortalization and in vitro passaging alienating them from 
the original patients sample (Pan et al., 2009). Furthermore, the number of available AL cell 
lines is inadequate regarding the diversity of AL subtypes (Gillet et al., 2011; Hausser and 
Brenner, 2005). 
Mouse models have the advantages to study leukemia cells within a complex living system 
including extrinsic factors like the microenvironment. They can be divided into syngeneic 
models, where a mouse leukemia is studied in the presence of a functional immune system, and 
xenograft models, where human leukemia cells are transplanted and studied in mice without 
functional immune system (Jacoby et al., 2014). For syngeneic mouse models, leukemia 
associated genes, which are known to be potential drivers of leukemogenesis, are modified, 
either through transgenic mice, or by genetic modification of primary HSC followed by 
transplantation into recipient mice, or by chemical carcinogens (Jacoby et al., 2014). To study 
human AML and ALL cells close to the patients’, the currently best available model system is 
the patient-derived xenograft (PDX) mouse model of AL (Lee et al., 2007; Liem et al., 2004; 
Townsend et al., 2016). 
2.3.1 Patient-derived xenograft (PDX) mouse model of AL 
PDX are generated by the injection of primary AL cells derived from patients into 
immunodeficient mice. By serial re-passaging of leukemic cells from mouse to mouse, the PDX 
sample is amplified (Siolas and Hannon, 2013). The first immunodeficient mice which could 
be used for the engraftment of leukemic cell, were mice with a mutation leading to severe 
combined immunodeficiency (SCID) (Bosma et al., 1983). This mouse enabled the engraftment 
of human hematopoietic cells, leukemia cell lines, and primary patient cells (Kamel-Reid et al., 
1989). But due to remaining immunity of the mice, engraftment rates were poor, which led to 
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the development of mouse strains with even stronger immunodeficiency. Here, the SCID mouse 
was backcrossed onto a nonobese diabetic (NOD) background, resulting in the NOD/SCID 
mouse with higher engraftment rates (Shultz et al., 1995). This mouse strain was further develop 
to generate mice with an almost completely absent immune system by additional mutation of 
the interleukin-2 receptor gamma chain. These NOD/SCID/gamma chain depleted (NSG) mice 
do virtually not have any mature T cells, B cells or natural killer cells, and an impaired innate 
immunity (Shultz et al., 2005), which leads to even increased engraftment rates of AML and 
ALL (Alruwetei et al., 2015; Schmitz et al., 2011; Terziyska et al., 2012; Townsend et al., 2016; 
Vick et al., 2015). In contrast to xenograft models of solid tumors, the development of the 
leukemia xenografts showed an orthotopic tumor distribution involving the bone marrow, 
blood, spleen and liver. Disease distribution is very similar to the situation in patients and the 
malignant cells reside in a similar microenvironment within the mouse bone marrow (Baersch 
et al., 1997; Liem et al., 2004; Lock et al., 2002; Townsend et al., 2016).  
ALL PDX models have been used to model specific ALL subtypes. Engraftment and 
distribution levels correlate with the clinical outcome in patients. Additionally, the ALL PDX 
model is used to predict clinical chemotherapy response in patients (Liem et al., 2004; Woiterski 
et al., 2013) and to search for biomarkers that enable the prediction of response and resistance 
towards treatment (Townsend et al., 2016). Established ALL PDX samples are highly reliable, 
allowing the prediction of engraftment and the monitoring of the engraftment by blood analysis 
(Castro Alves et al., 2012; Lock et al., 2005; Terziyska et al., 2012). Especially in NSG mice, 
engraftment rates for different types of primary ALL samples are high. Townsend et al. reported 
engraftment rates of 67.5 % for B-ALL and even 46.7 % for the previous difficult to engraft T-
ALL (Townsend et al., 2016). 
AML PDX models have been used to identify specific immunophenotypes on leukemia 
initiating cells (LIC) and certain surface markers indicating LIC. Higher numbers of stem cells 
identified by appropriate markers in primary samples correlated with higher engraftment rates 
in mice (Bonnet and Dick, 1997; Hope et al., 2003; Lapidot et al., 1994). Surface markers are 
also used for the identification of biomarkers, to predict response and resistance after treatment 
and to predict the success of treatment for genetically different subtypes (Townsend et al., 
2016). In addition AML PDX models are an attractive tool for the development of new 
treatment strategies targeting leukemia stem cells (LSC) (Hope et al., 2003). Compared to ALL 
PDX models, AML models are more difficult to handle, need longer engraftment times, and 
have a lower engraftment rate (Lee et al., 2007). In NSG mice, the engraftment rate for 
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repetitively transplantable primary AML samples is 23.2 %, which nowadays allowed the 
establishment of a large repository of established AML PDX samples (Townsend et al., 2016).  
PDX models of human AL provide an important tool to investigate numerous aspects of the 
complex biology of AL. They enable amplification of human leukemic cells and have been used 
for identify clinically relevant risk groups to evaluate new treatment strategies (Meyer and 
Debatin, 2011). AML PDX and ALL PDX cells have been shown to retain important 
characteristics of primary AL cells and to recapitulate most clinical aspects of the leukemia 
(Castro Alves et al., 2012; Meyer and Debatin, 2011; Schmitz et al., 2011; Terziyska et al., 
2012; Vick et al., 2015). 
In summary, the NSG PDX model represents an especially suitable model to study leukemic 
cells in vivo. PDX AL cells are very closely related to the primary patients’ leukemia and 
represent an important tool to investigate questions on the complex biology of AL.  
2.3.2 PDX model to identify a rare subpopulation of dormant ALL cells 
The hosting lab where the current study was performed, established the PDX mouse model of 
AL for several years, both for acute myeloid (AML) and acute lymphoblastic leukemia (ALL) 
(Castro Alves et al., 2012; Terziyska et al., 2012; Vick et al., 2015). Before the study started, 
they had begun using the model to search for surrogates of relapse-inducing cells using 
dormancy as anchor. The underlying idea was that long-term dormant cells in the PDX AL 
model might represent relapse-inducing cells in patients, with the major advantage that PDX 
cells would allow repetitive and functional studies. 
The study was started by Sebastian Tiedt. His first aim was to establish a method to isolate 
minute numbers of PDX cells from bone marrow. Towards this aim, he chose a molecular 
approach and expressed three different marker transgenes in PDX cells by lentiviral 
transduction (Figure 1). The advantage of the molecular approach was that it allowed an 
unbiased isolation of entirely all human PDX cells independent from the expression of 
endogenous surface antigens, which might be restricted to yet undefined leukemia 
subpopulations.  
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Figure 1: Generation of transgenic PDX ALL with high expression of artificial transgenes  
A Scheme of the lentiviral constructs applied for expression of transgenes; arrow indicates start of transcription; 
EF1α = elongation factor 1-alpha promoter; mKate = red fluorescent protein cloned from sea anemone Entacmaea 
quadricolor; mCherry = red fluorescent protein cloned from Discosoma sp.; NGFR = a truncated form of the 
human low affinity nerve growth factor receptor lacking the intracellular signaling domain. 
B Exemplary FACS blot (upper panel) and bioluminescence in vivo imaging (lower panel) of enriched transgenic 
PDX ALL-199 cells (upper panel) and PDX ALL-265 cells (lower panel). 
C Schematic workflow for the generation of genetically engineered PDX ALL cells. Primary patients ALL cell 
were injected i.v. into immunodeficient NSG mice. After engraftment and proliferation, PDX cells were serially 
passaged in further recipient mice. Furthermore, PDX cells were transduced with lentiviral constructs as depicted 
in B. PDX cells expressing the transgenes were enriched by FACS sorting and amplified.  
 
As transgenic markers, he decided for expressing (i) the fluorescent protein mKate or mCherry 
for cell tracking and enriching by flow cytometry (Fehse et al., 1997); (ii) the artificial antigen 
NGFR for cell enrichment by magnetic cell sorting; and (iii) luciferase for repetitively 
monitoring disease progression in the same mouse (Figure 1A, B) (Rabinovich et al., 2008; 
Terziyska et al., 2012). A schematic workflow how transgenic PDX samples were generated is 
depicted in Figure 1C. In brief, PDX cells were lentivirally transduced ex vivo either with just 
one construct containing mCherry and the luciferase or with two constructs, one containing the 
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red fluorescent protein mCherry and a luciferase and the other containing the truncated 
extracellular receptor nerve growth factor receptor (NGFR) (Figure 1A). As transduction 
efficiencies in PDX cells are often low, in average around 30 %, but sometimes even less than 
5 %, flow cytometry was used to enrich transduced PDX cells to more than 95 % purity. 
Sebastian Tiedt next transplanted PDX ALL cells expressing all three transgenes into NSG 
mice and re-isolated them back again from mouse bone marrow at early time points in the 
leukemic disease when only very low numbers of PDX cells were yet present. He isolated 
mouse bone marrow and enriched human PDX ALL cells in a first step by magnetic beads 
coupled with an antibody directed against NGFR. In a second step, he enriched PDX ALL cells 
further by sorting fluorochrome positive cells by flow cytometry. Using this approach, he 
enriched low numbers of PDX cells from mouse bone marrow by a factor well above 10.000 
(Tiedt, 2014).  
Once the method was established, Sebastian Tiedt started to search for long-term dormant PDX 
ALL cells using stainings with the proliferation-dependent dye Carboxyfluorescein-
Succinimidyl Ester (CFSE) (Tiedt, 2014).  
 
Figure 2: Schematic workflow of staining with CFSE and enriching rare transgenic, CFSE stained PDX 
cells from mouse bone marrow 
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CFSE remains covalently bound inside of cells in vivo over several months (Takizawa et al., 
2011) and is distributed onto daughter cells upon cell division. Figure 2 shows the staining and 
detection workflow for CFSE. 
Using CFSE as label and a first kinetic, Sebastian Tiedt indeed found a rare subpopulation of 
PDX ALL cells that did not participate in tumor growth, but instead remained dormant over 
prolonged periods of time (Tiedt, 2014) – which represented the starting point of my work 
described below. 
Taken together, the working group of the hosting laboratory for this study had generated tools 
and techniques which enables re-isolating minute numbers of PDX cells from mouse bone 
marrow using molecular markers as anchors and has established CFSE staining in the PDX 
model for identifying long-term dormant ALL cells. 
2.4 Aim of this work 
In acute leukemias, treatment resistant cells, which might persist as minimal residual disease 
(MRD), might later be responsible for relapse and thereby determine the prognosis of patients. 
Chemotherapy resistance is considered to be closely related to dormancy, but the responsible 
biological mechanisms are still unclear. To prevent relapse and improve the outcome in 
patients, new treatment strategies for elimination of chemotherapy resistant cells are urgently 
needed. However until now technical limitations impede the isolation and detailed 
investigations on relapse-inducing cells in AML and ALL. 
The first aim of the present work was to develop the individualized patient-derived xenograft 
(PDX) model further by optimizing the isolation of minimal human PDX cells from mouse 
bone marrow.  
This technique together with the label retaining dye CFSE was then used to evaluate the in vivo 
growth behavior of ALL and AML PDX in the bone marrow of NSG mice. 
The study aimed to investigate, whether PDX samples derived from different patients with ALL 
or AML would frequently contain a subpopulation of dormant cells. To characterize dormant 
cells on a functional level, the study investigated, whether dormant PDX ALL and AML cells 
displayed a behavior that challenges current anti-leukemia treatment, such as drug resistance, 
stem cell properties and relapse-inducing potential. Furthermore, the study addressed the 
question whether adverse characteristics of the dormant subpopulation were transient or 
constant and which influence the bone marrow environment might have on growth behavior of 
PDX AL cells. 
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The developed model and the consequent findings will be of translational importance as they 
establish a basis to develop new treatment strategies to eradicate relapse-inducing cells. 
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3 Material 
3.1 Mice 
NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ (NSG)  (Shultz et al., 2005) 
 
NSG mice have a severe combined immunodeficiency/non-obese diabetic (NOD/SCID) 
background with an interleukin-2 receptor gamma chain knockout. As a result mice are 
immunodeficient; they have no mature T cells, B cells or natural killer cells and are deficient 
in cytokine signaling. Mice were obtained from the Jackson Laboratory (Charles River 
Laboratories France). 
3.2 Cell lines 
HEK-293T     DSMZ, Braunschweig, Germany 
(SV40 large T-antigen expressing 
human embryonic kidney cells)        
Nalm-6 (B cell precursor leukemia cells) DSMZ, Braunschweig, Germany 
3.3 Plasmids and primer 
Plasmid 
pRSV-Rev (392)    Addgene, Cambridge, MA, USA 
pMDLg/pRRE (393)    Addgene, Cambridge, MA, USA 
pMD2.G     Addgene, Cambridge, MA, USA 
pCDH-EF1α-extGlucT2A-mCherry  cloned by Michela Carlet 
pCDH-EF1α- NGFR    cloned by Michela Carlet 
 
Primer for finger printing of mitochondrial DNA 
Primer 456     5’TCCACCATTAGCACCCAAAGC3’ 
Primer 457     5’TCGGATACAGTTCACTTTAGC3’ 
 
3.4 Antibodies 
CD33hu-PE,     BD Bioscience, Heidelberg, Germany 
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 clone: WM-53, #555450  
CD38hu-PE,       BD Bioscience, Heidelberg, Germany 
clone: HB7, #345806 
CD45hu-APC,    BD Bioscience, Heidelberg, Germany 
clone: HI30, #555485 
CD45mu-APC,     Biolegend, San Diego, CA, USA 
clone: 30-F11,#103112 
CD45mu-APC-Cy7,    Biolegend, San Diego, CA, USA 
clone: 30-F11, #103115  
CD271hu-PerCP/Cy5.5 (NGFR)  Biolegend, San Diego, CA, USA 
 clone: ME20.4, #345111 
 
Mouse IgG1 APC Isotype Control,  BD Bioscience, Heidelberg, Germany 
clone: MOPC-21, #555751  
Mouse IgG1 APC Isotype Control,   Biolegend, San Diego, CA, USA 
clone: MOPC-21, #400119 
Mouse IgG1 PE Isotype Control,   BD Bioscience, Heidelberg, Germany 
clone: MOPC-21, #559320 
Mouse IgG1 PE Isotype Control,   Biolegend, San Diego, CA, USA 
clone: MOPC-21, #400140 
 
Mouse cell depletion kit   Miltenyi, Bergisch Gladbach, Germany 
NGFR Beads     Miltenyi, Bergisch Gladbach, Germany 
3.5 Buffer and media 
DMEM medium for cultivation of AL cell line cells      
DMEM (Gibco, San Diego, USA), 10 % FCS (Biochrome, Berlin, Germany), 1 % 
glutamine (Gibco, San Diego, USA) 
Glucose-containing Hepes buffer 
H2O, 5 % Glucose (Braun, Melsungen, Germany), 20 mM Hepes pH 7.1 (Gibco, San 
Diego, USA) 
Medium for cultivation of ALL PDX cells 
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RPMI-1640 (Gibco, San Diego, USA), 20 % FCS (Biochrome, Berlin, Germany), 2 mM 
glutamine (Gibco, San Diego, USA), 1 % penicillin-streptomycin (Gibco, San Diego, 
USA), 1 % gentamicin (Lonza, Allendale, USA), ITS-G (=6 mg/l insulin, 3 mg/l 
transferrin, 4 µg/l selenium) (Gibco, San Diego, USA), 1 mM sodium pyruvate (Sigma-
Aldrich, St. Louis, USA), 50 µM α-thioglycerol (Sigma-Aldrich, St. Louis, USA) 
Medium for cultivation of AML PDX cells 
StemPro-34 medium (Thermo Fischer Scientific, Waltham, USA), 1 % penicillin-
streptomycin (Gibco, San Diego, USA), 1 % glutamine (Gibco, San Diego, USA), 2 % 
FCS (Biochrome, Berlin, Germany), 10 µg/l recombinant human Flt-3 Ligand (R&D 
Systems, Minneapolis, USA), 10 µg/l Recombinant human SCF (PeproTech, Rocky Hill, 
USA), 10 µg/l Recombinant human TPO (PeproTech, Rocky Hill, USA), 10 µg/l 
Recombinant human IL-3 (PeproTech, Rocky Hill, USA) 
PDX short-term storage medium 
RPMI-1640 (Gibco, San Diego, USA), 20 % FCS (Biochrome, Berlin, Germany), 1 % 
penicillin-streptomycin (Gibco, San Diego, USA), 1 % gentamicin (Lonza, Allendale, 
USA), 2 mM glutamine (Gibco, San Diego, USA) 
Phosphate-buffered saline (PBS) 
H2O, 137 mM NaCl (Carl Roth, Karlsruhe, Germany), 2.7 mM KCl (Merck Milipore, 
Darmstadt, Germany), 10 mM Na2HPO4 (Sigma-Aldrich, St. Louis, USA), 1.8 mM 
KH2PO4 (Merck Milipore, Darmstadt, Germany) 
 Phosphate-buffered saline with EDTA (PBE) 
 PBS, 0.5 % BSA, 5 mM EDTA (Lonza, Allendale, USA) 
3.6 Kits 
BrdU APC Flow Kit    BD Bioscience, Heidelberg, Germany 
CellTrace CFSE Cell Proliferation Kit Life Technologies, Carlsbad, CA, USA 
for flow cytometry 
MinElute PCR Purification kit  Qiagen, Venlo, NL 
QIAamp DNA Blood Mini Kit  Qiagen, Venlo, NL 
3.7 Chemotherapeutics 
Cytarabine     cell pharm GmbH, Bad Vilbel, Germany 
Daunorubicine    PFIZER PHARMA GmbH, Berlin, Germany 
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DaunoXome     Galen, Craigavon, UK 
Doxorubicine     Accord Healthcare GmbH, Freilassing, Germany 
Epirubicine     TEVA GmbH, Ulm/Donau, Germany 
Etoposide     TEVA GmbH, Ulm/Donau, Germany  
Mitoxantrone     TEVA GmbH, Ulm/Donau, Germany 
Vincristine     cell pharm GmbH, Bad Vilbel, Germany 
3.8 Reagents and chemicals 
α-thioglycerol     Sigma-Aldrich, St.Louis, USA 
Baytril (2.5 %)    Bayer, Leverkusen, Germany 
BrdU      VWR, Radnor, USA 
BSA      Carl Roth, Karlsruhe, Germany 
Coelenterazine    Synchem OHG, Felsberg, Germany 
DAPI (4',6-diamidino-2-phenylindole) Sigma-Aldrich, St. Louis, USA 
 (1mg/ml) 
D-Luciferin     BIOMOL GmbH, Hamburg, Germany 
DMSO     Sigma-Aldrich, St. Louis, USA 
DNase I     Roche, Mannheim, Germany 
DNase I buffer    Roche, Mannheim, Germany 
dNTPs  (10 mM each)   Biozym, Hessisch Oldendorf, Germany  
EDTA (0.5 M)    Lonza, Allendale, USA 
FACS Lysing Solution 10x   BD Bioscience, Heidelberg, Germany 
FCS      Biochrome, Berlin, Germany 
Ficoll      GE Healthcare, Freiburg, Germany 
Gentamicin     Lonza, Allendale, USA 
Glucose (20 %)    Braun, Melsungen, Germany 
Glutamine     Gibco, San Diego, USA 
GoTaq  G2 DNA Polymerase  Promega, Madison, USA 
 + Reaction Buffer (5x) 
Heparin     Ratiopharm, Ulm, Germany    
Hepes (1 M)     Gibco, San Diego, USA 
Isopropyl alcohol    Merck Milipore, Darmstadt, Germany  
ITS-G (insulin-transferrin-selenium; 100x) Gibco, San Diego, USA 
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KCl      Merck Milipore, Darmstadt, Germany 
KH2PO4     Merck Milipore, Darmstadt, Germany 
NaCl      Carl Roth, Karlsruhe, Germany 
Na2HPO4     Sigma-Aldrich, St. Louis, USA 
Penicillin-Streptomycin (5000 U/ml) Gibco, San Diego, USA 
Polybrene (2 mg/ml)    Sigma-Aldrich, St. Louis, USA 
Recombinant human Flt-3 Ligand  R&D Systems, Minneapolis, USA 
Recombinant human IL-3   PeproTech, Rocky Hill, USA  
Recombinant human SCF   PeproTech, Rocky Hill, USA 
Recombinant human TPO    PeproTech, Rocky Hill, USA 
Sodium pyruvate (100 mM)   Sigma-Aldrich, St. Louis, USA 
Turbofect     Thermo Fischer Scientific, Waltham, USA 
Trypsin (1x)     Invitrogen, Karlsruhe, Germany 
Trypan blue     Sigma-Aldrich, St. Louis, USA  
3.9 Consumables 
Amicon-Ultra 15 centrifugal filter units  Merck Millipore, Darmstadt, Germany 
Cell strainer     Greiner bio-one, Frickenhausen, Germany 
Centrifuge tubes (15 ml and 50 ml)  Greiner bio-one, Frickenhausen, Germany  
Cryotubes     Thermo Fischer Scientific, Waltham, USA  
Disposable serological pipettes  Greiner bio-one, Frickenhausen, Germany 
 (5 ml, 10 ml, 25 ml, 50 ml) 
LS columns     Miltenyi, Bergisch Gladbach, Germany 
Microvette, Lithium-Heparin (100 µl) Sarstedt, Nümbrecht, Germany  
Needles RN G32 PST3 51MM  Hamilton, Reno, USA 
Petri dishes     Greiner bio-one, Frickenhausen, Germany 
Pipette filter tips TipOne   Starlab, Hamburg, Germany 
(10, 20, 200, 1000)  
Well-Plates for tissue culture   Corning, Corning, USA 
 (6-well, 12-well, 24-well) 
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3.10 Equipment  
Biological safety cabinet Safe 2020 Thermo Fisher Scientific, Langenselbold, 
Germany 
Cell sorter BD FACSAriaIII BD Bioscience, Heidelberg, Germany 
Centrifuge Rotanta 460R Andreas Hettich GmbH & Co. KG, Tuttlingen, 
Germany  
Quietek CO2 Induction Systems  Next Advance, Averill Park, USA 
Flow cytometry BD Calibur   BD Bioscience, Heidelberg, Germany  
Flow cytometry BD LSRFortessa  BD Bioscience, Heidelberg, Germany 
Incubator HERA CELL 150i Thermo Fisher Scientific, Langenselbold, 
Germany 
In vivo Imager   Caliper Life Sciences, Mainz, Germany 
IVIS Lumina II Imaging System 
Light microscope 550 1317   Zeiss, Jena, Germany 
Micro Scales Sartorius 2001 MP2  Sartorius AG, Göttingen, Germany 
NanoDrop ND-1000 Thermo Fisher Scientific, Langenselbold, 
Germany 
Table Centrifuge mini Spin   Eppendorf, Hamburg, Germany  
Thermocycler Primus 25 advanced  Peqlab, Erlangen, Germany 
3.11 Software 
Name      Application 
FlowJo V10     Analysis of flow cytometry 
GraphPad Prism 6    Drawing of graphs, statistical analysis 
Living Image software 4.4   Analysis of in vivo imaging 
Microsoft Office    Figure drawing, calculations, writing 
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4 Methods 
4.1 Ethical statements 
4.1.1 Patient material 
Patients’ acute leukemic cells were collected from peripheral blood or bone marrow aspirates 
that had been obtained from leftovers of clinical routine sampling before onset of therapy. 
Written informed consent was obtained from all patients and from parents/carers in the cases 
where patients were minors. 
For AML, primary AML blasts were obtained from patients treated at the Department of 
Internal Medicine III, Ludwig-Maximilians-Universität, Munich.  
For ALL, primary ALL blasts were obtained from children treated at the Dr. von Haunersches 
Kinderspital, Ludwig-Maximilians-Universität, Munich or for one sample from a child treated 
at the University Children’s Hospital in Zurich.  
The study was performed in accordance with the ethical standards of the responsible committee 
on human experimentation (written approval by Ethikkommission des Klinikums der Ludwig-
Maximilians-Universität München, Ethikkommission@med.uni-muenchen.de, April 2008 
(068-08) and September 2010 (222-10)) and with the Helsinki Declaration of 1975, as revised 
in 2000.  
4.1.2 Animal work 
All animal trials were performed in accordance with the current ethical standards of the official 
committee on animal experimentation (written approval by Regierung von Oberbayern, 
poststelle@reg-ob.bayern.de; July 2010, number 55.2-1-54-2531-95-10; July 2010, number 
55.2-1-54-2531.6-10-10; January 2016, number 55.2-1-54-2532-193-2015; May 2010, number 
55.2-1-54-2532-193-2015 and August 2016, number 55.2-1-54-2532.0-56-2016). 
4.2 The NSG mouse model of individual acute leukemias 
For amplification of patients’ acute leukemias cells, the previously described NSG (see 3.1 
Mice) mouse model was used, which had been established in the hosting laboratory (Shultz et 
al., 2005; Terziyska et al., 2012; Vick et al., 2015). 
NSG mice were maintained under specific pathogen-free conditions in the research animal 
facility of the Helmholtz Zentrum München, Munich, Germany. Animals had free access to 
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food and water, and were housed with a 12-hour light-dark cycle and constant temperature. 
After injection, mice were treated with Baytril to prevent infections. Therefore 1 ml of 2.5 % 
Baytril solution was added to 250 ml drinking water. 
4.2.1 Expansion of primary patient cells and PDX cells 
For amplification of leukemic blast from acute leukemia patients, up to 107 cells from peripheral 
blood or bone marrow aspirates were re-suspended in 100 µl autoclaved and filtered PBS and 
injected into 6-16 weeks old NSG mice via the tail vein.  
For amplification of PDX cells, 102 - 107 cells were injected. 
Engraftment was monitored by up to 2-weekly flow cytometry measurement of human cells in 
peripheral blood (see 4.2.3 Flow cytometry of human cells in mouse peripheral blood). Mice 
were sacrificed (see 4.2.4 Sacrificing mice by CO2 exposure) at (i) defined days post-injection 
for specific experiments, (ii) first clinical signs of disease (rough fur, hunchback, or reduced 
motility) or (iii) at signs of advanced leukemia, as measured by quantification of human cells 
in peripheral blood or by in vivo imaging. If leukemia became not apparent, mice were killed 
and analyzed 25 weeks after cell injection by latest. From engrafted mice, leukemic cells were 
harvested from enlarged spleens (see 4.2.5 Isolation of PDX cells from mouse spleen) or from 
bone marrow (see 4.2.6 Isolation of PDX cells from mouse bone marrow). Re-passaging was 
successful in all engrafted samples. Accuracy of sample identity was verified by repetitive 
finger printing using PCR of mitochondrial DNA (see 4.2.2 Repetitive finger printing using 
PCR of mitochondrial DNA) (Hutter et al., 2004). 
4.2.2 Repetitive finger printing using PCR of mitochondrial DNA 
For early detecting putative, involuntary sample mix-ups and for a regular authentication of 
PDX samples, distinct areas of mitochondrial DNA was routinely sequenced and analyzed for 
sample-specific single nucleotide variants (Hutter et al., 2004). 
DNA was prepared of 107 PDX cells with the Qiagen QIAamp DNA Blood Mini Kit according 
to manufacturer’s instructions. DNA concentration was measured at the NanoDrop and DNA 
was stored at -80 °C. 
The following 50 µl reaction mixture was used for Polymerase Chain Reaction (PCR): 
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Table 1: PCR reaction mix 
 
 
PCR was run Thermocycler with following program: 
 
Table 2: PCR reaction cycle 
 
 
PCR products were purified using the Qiagen MinElute 70-7000 bp according to 
manufacturer’s instructions. 100 ng/µl of purified PCR products were sent for Sanger 
sequencing to GATC (Biotech, Konstanz, Germany) using primer 456 and primer 457. 
Results from sequencing were analyzed by comparing them to the reference sequence of each 
patient sample. If the sequence was correct, the sample could be used for experiments; if the 
sequence was incorrect, cells were trashed and cells from earlier passages were sequenced and 
used. 
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4.2.3 Flow cytometry of human cells in mouse peripheral blood 
For quantification of human cells in mouse peripheral mouse blood, 50 µl blood from the tail 
vein was collected with a heparin coated glass capillary and pour into a lithium-heparin 
Microvette. 
The blood was incubated with 0.5 µl hCD38-PE and 0.5 µl mCD45-APC (ALL samples) or 
with 5 µl hCD45-APC and 3 µl hCD33-PE (AML samples) for 30 min in the dark at room 
temperature. 
1 ml FACS Lysing Solution was added to the stained blood samples and incubated for 15 min 
at room temperature for lysing the erythrocytes. The blood sample was washed twice with 3 ml 
FACS buffer at room temperature, and centrifuged at 300 g for 5 min. Afterwards flow 
cytometry analyses were performed with a FACSCalibur (see 4.4.7 Flow cytometry analysis) 
and the results were analyzed using the FlowJo software. If more than 1 % of human cells were 
detected, the sample was classified as engrafted.  
4.2.4 Sacrificing mice by CO2 exposure 
Mice were sacrificed by CO2 asphyxiation by the Quietek CO2 Induction Systems. The mouse 
to be sacrificed was placed in a CO2 empty cage (V = 7.67 l). The cage was closed with a 
Quietek lid, which was connected with the house CO2 system (100 % CO2) via a hose. 
Afterwards the Quietek CO2 Induction Systems was started. First the mouse/mice was/were 
anesthetized by a gas flow rate of 10 % of the chamber volume per minute (750 ml/min) for 
one minute. Afterwards the mouse/mice was/were sacrificed by a gas flow rate of 30 % of the 
chamber volume per minute (2250 ml/min) for four minutes. Before organs were removed, the 
clinical death of the mouse/mice was/were verified.  
4.2.5 Isolation of PDX cells from mouse spleen 
To isolate PDX cells from mouse spleen, the spleen was homogenized by smashing the organ 
through a 70 µm cell strainer with 10 ml PBS into a 50 ml Falcon tube, and filled up with PBS 
to 30 ml. Afterwards the cell suspension was under-laid with 10 ml Ficoll by a 51 mm needle 
and centrifuged (400 g, 30 min, RT, without rotor brake). After Ficoll gradient centrifugation 
mononuclear cells could be harvested as a layer at the interphase. The cells were washed twice 
with PBS (400 g, 5 min, RT). After washing, the cells were re-suspended in required buffer or 
PDX short-term storage medium depending on further use and counted using a Neubauer 
chamber (see 4.4.1 Determination of cell numbers). 
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4.2.6 Isolation of PDX cells from mouse bone marrow 
For isolation of PDX cells from mouse bone marrow, the isolated two femura, two tibiae, two 
hips, backbone and sternum were crushed using a mortar and pestle. The cells were suspended 
in PBS and filtered through a 70 µm cell strainer. The cells were washed twice with 10 ml PBS 
(400 g, 5 min, RT). After washing, the cells were re-suspended in required buffer or PDX short-
term storage medium depending on further use and counted using a Neubauer chamber (see 
4.4.1 Determination of cell numbers). 
4.2.7 Enrichment of PDX cells by magnetic cell separation (MACS) 
For enrichment of PDX cells from mouse bone marrow magnetic cell separation (MACS) was 
used. 
The isolated bone marrow cells from one mouse (see 4.2.6 Isolation of PDX cells from mouse 
bone marrow) harboring PDX cells transgenic for NGFR, were incubated with 200 µl anti-
human NGFR MicroBeads for 10 minutes at 4 °C. Cell suspension was divided onto two LS 
columns, prepared according to manufacturer’s instructions. Cells were recovered from the 
column according to manufacturer’s instructions and washed with PBS. 
The isolated bone marrow cells from one mouse (see 4.2.6 Isolation of PDX cells from mouse 
bone marrow) harboring PDX cells not transgenic for NGFR, were incubated with 100 µl mouse 
cell depletion kit MicroBeads for 20 minutes at 4 °C. Cell suspension was divided onto two LS 
columns, prepared according to manufacturer’s instructions. Cells were recovered from the 
column according to manufacturer’s instructions and washed with PBS. 
4.2.8 Enrichment of PDX cells by fluorescence-activated cell sorting (FACS) 
mCherry positive PDX cells from mouse bone marrow cell suspensions were enriched by flow 
cytometry. Cells obtained after MACS enrichment (see 4.2.7 Enrichment of PDX cells by 
magnetic cell separation (MACS)) were stained with 10 µg/ml DAPI to exclude dead cells. 
Cells were sorted using a BD FACSAriaIII, gating on lymphocytes in forward/side scatter, the 
gate negative for DAPI and positive for expression of mCherry (Figure 3).  
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Figure 3: Gating strategy to sort mCherry+ PDX cells from mouse bone marrow 
 
Alternatively, 10 % of the entire bone marrow cell suspension without prior MACS enrichment 
step was directly analyzed by flow cytometry with the identical staining and gating procedure. 
The entire cell suspension was recorded for quantifications. Depending on further use, sorted 
cells were either frozen (see 4.4.2 Freezing viable cells), re-injected into mice or used for 
different experiments. 
4.2.9 Isolation of dormant and proliferating cells 
Separating PDX cells into dormant label retaining cells (LRC) and fast proliferating non-LRC 
was performed within the FACS enrichment step (see 4.2.8 Enrichment of PDX cells by 
fluorescence-activated cell sorting (FACS)) by using two additional gates on CFSE positive or 
negative cells. To set the gate, CFSE intensity of CFSE labeled PDX cells either incubated for 
two to three days ex vivo or isolated from a mouse two to three days after injection was 
measured. Here major bleaching of CFSE was complete while a decisive CFSE indicated that 
proliferation was only minor or did not start yet. At day two or three the CFSE mean 
fluorescence intensity (MFI) was measured and defined as the absence of cell proliferation (“0 
divisions”). Day three CFSE MFI was divided by factor two to calculate CFSE bisections 
mimicking cell divisions (Figure 4).  
 
 
Figure 4: Gating strategy to define LRC and non-LRC gate 
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According to literature (Takizawa et al., 2011), seven CFSE MFI bisections were defined to 
correspond to the entire loss of the CFSE signal. Non-LRC were defined as all cells harboring 
CFSE content below seven CFSE MFI bisections. The LRC gate was set including all cells 
harboring high CFSE signal of below three CFSE MFI bisections so that a maximum of 3 cell 
divisions was allowed in LRC. 
4.2.10 Calculation of cell number doubling times in vivo 
For calculation of cell number doubling times in vivo, first absolute numbers of PDX cells re-
isolated from bone marrow after at least three different days after cell injection were determined 
according to 4.2.8 Enrichment of PDX cells by fluorescence-activated cell sorting (FACS). 
Then, growing curves with a logarithmic y-axis for isolated PDX cells were calculated in 
GraphPad Prism 6. From the linear range of these curves linear regression lines were calculated 
in GraphPad Prism 6. With help of the linear regression lines, exact y values were calculated 
for day 3 and day 7. Afterward the growth rate µ was calculated by following formula: 
 
μ = 	 (ln  − ln
)( −	
)  
y7 = calculated y-value for day 7 
y3= calculated y-value for day 3 
t7 = 7 
t3 = 3 
 
Finally the doubling time in days was calculated by following formula: 
 
	 = 	 ln 2μ  
4.2.11 Bioluminescence in vivo imaging 
In vivo imaging was used to detect and follow up leukemia in mice. In vivo imaging is based 
on the bioluminescence through the oxidation of substrates by luciferase enzymes. Cells can be 
tracked by cloning luciferase systems into these cells, the application of the respective 
substrates and the follow up detection of the emitted light by ultra-sensitive cameras (Kim et 
al., 2015).  
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The gaussia luciferase gene was originally cloned from the marine copepod Gaussia prince. It 
catalyzes the oxidation of coelenterazine in the present of oxygen. The light emission through 
the reaction ranges from 480 to 600 nm (Kim et al., 2015).  
The firefly luciferase gene was originally cloned from the North American firefly Photinus 
pyralis. It catalyzes the oxidation of D-luciferin in the presence of ATP, Mg2+ and oxygen and 
thereby emits light with a peak at 562 nm (Kim et al., 2015; Rabinovich et al., 2008). 
For in vivo imaging of NSG mice engrafted with PDX cells expressing gaussia or a recombinant 
codon-optimized form of firefly luciferase (effluc), the IVIS Lumina II Imaging System was 
used as previously described (Barrett et al., 2011; Bomken et al., 2013; Terziyska et al., 2012). 
Mice were anesthetized with isoflurane and immobilized in the imaging chamber. 
For imaging of PDX cells expressing gaussia luciferase, coelenterazine, dissolved in acidified 
methanol to a final concentration of 10 mg/ml, was used. Shortly before injection, 10 µl (= 100 
µg coelenterazine) was diluted in 200 µl sterile glucose-containing Hepes buffer and injected 
into the tail vein. Immediately after injection, mice were imaged for 15 seconds using a field of 
view of 12.5 cm with binning 8, f/stop 1 and open filter setting. Depending on imaging signal 
binning and f-stop were adjusted. 
For imaging of PDX cells expressing effluc (Rabinovich et al., 2008), D-Luciferin dissolved in 
sterile PBS to a final concentration of 30 mg/ml was injected at 150 mg/kg into the tail vein. 
Pictures were taken immediately for 15 sec or up to two minutes using a field of view of 12.5 
cm with binning 8, f/stop 1 and open filter setting. Depending on imaging signal binning and f-
stop were adjusted. 
The Living Image software 4.4 was used for data acquisition and quantification of light 
emission. 
4.2.12 In vivo treatment of mice 
NSG mice were injected intravenously (i.v.) with 1x107 PDX cells and were treated once or 
daily for three adjacent days starting on day seven after cell injection. 
Drug concentrations for treatment of mice were calculated from clinically relevant 
concentrations converting the human doses to mouse equivalent doses based on body surface 
area (Sharma and McNeill, 2009). Therefore first the human dose in mg/m2 was converted into 
the human dose in mg/kg using the human km factor of 37: 
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ℎ			 = 	
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37  
 
Next the human dose in mg/kg was converted into the mouse equivalent dose in mg/kg using 
the conversion factor 12.3: 
 
			 = ℎ			

 	 	12.3 
 
Control animals received PBS intraperitoneal (i.p.) or i.v. and all cytotoxic drugs were diluted 
in sterile PBS. Vincristine (VCR), etoposide (ETO), cyclophosphamide (CYCLO), cytarabine 
(ARA-C), amsacrine (AMSA), epirubicin (EPI), and DaunoXome (DNX) were used for 
treatment of mice depending on injected sample. Unless otherwise noted, the treatment scheme 
listed in Table 3 were applied. 
Mice were taken down 3 days after treatment start, bone marrow was collected, and PDX cells 
were isolated (4.2.6 Isolation of PDX cells from mouse bone marrow) and analyzed (4.4.7 Flow 
cytometry analysis).  
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Table 3: Treatment scheme of mice injected with PDX samples 
 
4.2.13 Limiting dilutions transplantation assay (LDTA) 
NSG mice were injected i.v. with limiting numbers of PDX cells. Development of leukemia 
was monitored by bioluminescence in vivo imaging (see 4.2.11 Bioluminescence in vivo 
imaging) every 7 to 14 days after cell injection or by quantification of human cells in peripheral 
mouse blood (see 4.2.3 Flow cytometry of human cells in mouse peripheral blood) every second 
week. Here, first the mice with the highest amount of injected cells were analyzed. When these 
mice showed a positive engraftment, mice who received the next dilution were analyzed too. 
Leukemia initiating cells (LIC) frequencies were determined according to Poisson statistics, 
using the ELDA software application (http://bioinf.wehi.edu.au/software/elda/) (Hu and Smyth, 
2009). 
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4.2.14 5-Bromo-2'-desoxyuridine (BrdU) labeling of proliferating PDX DNA 
To label DNA of proliferating PDX cells with BrdU, mice engrafted with PDX cells were fed 
with BrdU-containing drinking water (0.8 mg/ml) during the last seven days before cell 
isolation. BrdU was dissolved in H2O to a concentration of 12 mg/ml and stored at 4 °C. BrdU 
solution was diluted in drinking water of mice to a final concentration of 0.8 mg/ml every day, 
as BrdU is unstable at room temperature. 
4.3 Genetic engineering of PDX cells 
All genetic engineering procedures and constructs were approved by the Regierung von 
Oberbayern (written approvals September 2008, number 55-8791-8.549.1460, January 2010, 
number 55-8791-8.549.1562, and June 2016, number 55.1-8791-8.549.2261. All work with 
lentiviruses was performed under S2 conditions.  
For genetic engineering of PDX cells, a third generation lentivirus system was used (Dull et al., 
1998; Zufferey et al., 1999). 
4.3.1 Lentivirus production in HEK-293T cells 
For production of lentiviruses, the adherent cell line HEK-293T was used as packaging cell 
line. HEK-293T cells were grown in DMEM medium in a 75 cm2 culture flask. When cells 
reached 50-80 % confluency, medium was exchanged and transfection solution was prepared. 
For this purpose the packaging plasmids 392 (2.5 µg), 393 (5 µg) and pMD2.G (1.25 µg) and 
the respective transfer vector (2.5 µg) were mixed with 24 µl Turbofect and filled up with 
DMEM to a final volume of 1 ml. The solution was incubated for 20 min at RT and afterwards 
added dropwise to the cells in one culture flask. After incubation for three days cell suspension 
was transferred into a Falcon tube and centrifuged (400 g, 5 min, RT). Supernatant was filtered 
through a 0.45 µm filter and concentrated by centrifugation (2000 g, 30 min, RT) using 
Amicon-Ultra 15 centrifugal filter units until a remaining volume of 200-250µl. The 
concentrated virus was frozen in aliquots of 10 µl and stored at -80 °C.  
4.3.2 Determination of lentivirus titer 
For quality monitoring, the virus titer of the produced lentiviruses (see 4.3.1 Lentivirus 
production in HEK-293T cells) was determined on Nalm-6 cells. 0.5 x 106 cells in 0.5 ml RPMI 
were plated in 5 wells of a 24-well plate. Increasing amounts of virus (control, 1 µl, 3 µl, 10 µl, 
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25 µl) and 8 µg/ml polybrene were added to the cells. 4 days after transduction, cells were 
washed three times with PBS (400 g, 5 min, RT) and the percentage of positive transduced 
Nalm-6 cells was determined by flow cytometry (see 4.4.7 Flow cytometry analysis) for each 
virus concentration. The virus titer was calculated by following formula: 
 
#	 = 	 $%	 ∙ '( ) 	*+/ 
 
F = % of transduced cells 
Z = number of cells at infection 
V = Volume of virus in ml 
 
For this study virus titer between 108 TU/ml and 3x108 TU/ml were used. 
4.3.3 Lentiviral transduction of PDX cells 
107 freshly re-isolated PDX cells were resuspended in 1 ml of medium for cultivation of ALL 
PDX cells or medium for cultivation of AML PDX cells were plated in a 6-well plate. 20 µl of 
virus (see 4.3.1 Lentivirus production in HEK-293T cells) containing the required transgene(s) 
and 8 µg/ml polybrene were added to the cells. 24 h after transduction, cells were washed three 
times with PBS (400 g, 5 min, RT), re-suspended in 100 µl PBS and injected into a mouse. 
Transduction rate was assessed by determining percentage of transgene expression by flow 
cytometry (see 4.4.7 Flow cytometry analysis). 
4.3.4 FACS sorting to enrich genetically engineered cells 
For enrichment of transgene expressing cells (see 4.3.3 Lentiviral transduction of PDX cells) 
sorting via a BD FACSAriaIII was performed. Freshly isolated (see 4.2.5 Isolation of PDX cells 
from mouse spleen or 4.2.6 Isolation of PDX cells from mouse bone marrow) or thawed (see 
4.4.3 Thawing cells) PDX cells were filtered through a 70 µm cell strainer. PDX cells which 
were transfected with pCDH-EF1α-NGFR were stained for NGFR (see 4.4.6 Antibody staining 
of cells and staining of dead cells). Afterwards cells were washed with PBS (400 g, 5 min, RT). 
PDX cells were re-suspended in PBS or PDX short-term storage medium to a concentration of 
107 cells/ml. Cells were stained with DAPI to exclude dead cells (see 4.4.6 Antibody staining 
of cells and staining of dead cells). For sorting a 100 µm nozzle and the adjustment “purity” 
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was used. The cells were sorted into medium for cultivation of ALL PDX cells or PBS 
supplemented with 10 % FCS.  
4.4 Ex vivo methods 
4.4.1 Determination of cell numbers 
Cell numbers were determined by a “Neubauer” counting chamber.  
From cell solutions a suitable concentration from 0.25 x 106 cells/ml to 1 x 106 cells/ml was 
prepared and 10 µl were filled into the counting chamber covered with a glass cover. Using a 
light microscope, cells in all 4 squares were counted. Here cells touching the lower and right 
limits were included, unlike cells touching the upper and left limit. If number of counted cells 
in all 4 squared was below 100, the cell concentration was too low. If number of counted cells 
in all 4 squared was above 400, the concentration was too high. 
For counting living cell, cell dilutions were mixed 1:1 (v/v) with 0.4 % trypan blue (w/v) before 
filling them into the counting chamber. Under the microscope living cells appear colorless and 
bright whereas dead cells were stained blue. 
Cell concentration was calculated as follows: 
 
-	-- = 	 (	.	-	-)	 	(	.-)	 	100	-/ 
4.4.2 Freezing viable cells 
Cells for later sorting (see 4.3.4 FACS sorting to enrich genetically engineered cells) were 
frozen at 5 x 107 cells/ml and all other cells were frozen at 107 cells/ml. Cell pellets were re-
suspended in 0.5 ml FCS per cryotube. Afterwards 0.5 ml freezing medium (80 % FCS + 20 % 
DMSO v/v) per cryotube were prepared and added dropwise to the cell suspension. 1 ml of the 
cell suspension was transferred into each cryotube. For a cooling rate of 1°C/min, cryotubes 
were placed into a freezing container, filled with isopropyl alcohol and stored at -80 °C. After 
24 h cryotubes were removed from freezing container and either stored at -80 °C for short term 
storage or in liquid nitrogen at -196 °C for long-term storage. 
4.4.3 Thawing cells 
To obtain cells with high viability, they were thawed by the thawing protocol of Dominique 
Bonnet (Bonnet, 2008). 
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Frozen cells (see 4.4.2 Freezing viable cells) were rapidly thawed in a 37 °C water bath. 100 µl 
DNase (1 mg/ml) were added dropwise to the thawed cells and mixed. Cells were transferred 
into a 50 ml tube and 1 ml FCS was added dropwise. After waiting for 1 min 10 ml PBS 
supplemented with 2 % FCS was added slowly. After waiting for 1 min cell suspension was 
slowly filled up to 30 ml with PBS + 2 % FCS. Afterwards cells were centrifuged (200 g, 4 min, 
RT). 
4.4.4 Ex vivo culture of PDX cells 
For ex vivo culture, PDX cells were diluted in medium at a concentration of 106 cells/ml. ALL 
PDX cells were incubated in medium for cultivation of ALL PDX cells and AML PDX cells in 
medium for cultivation of AML PDX cells. Cells were transferred into well plates and incubated 
at 37 °C, 5 % CO2. 
Ex vivo culture of PDX cells did not exceed three days, therefore no medium change was 
necessary.  
4.4.5 5-(6)-Carboxyfluorescein-Succinimidyl Ester (CFSE) staining of cells 
For labeling cells with 5-(6)-Carboxyfluorescein-Succinimidyl Ester (CFSE), freshly isolated 
PDX cells were suspended in pre-warmed (37 °C) PBS supplemented with 0.1 % BSA at a 
concentration of 106 cells/ml. Carboxyfluorescein diacetate succinimidyl ester (CFDASE) was 
suspended in DMSO to a concentration of 5 mM. Afterwards the diluted CFDASE was added 
to the cell suspension to a final concentration of 10 µM and incubated for 10 minutes at 37 °C. 
After incubation the staining was stopped by adding five times the original staining volume of 
cold RPMI supplemented with 10 % FCS and incubation for 5 min on ice. This step removes 
any free dye. Cells were centrifuged (400 g, 5 min, RT) and re-suspended in PBS for direct 
injection into recipient mice, or in appropriate medium. 
4.4.6 Antibody staining of cells and staining of dead cells 
A NGFR staining 
PDX cells transfected with pCDH-EF1α-NGFR, were stained with 5 µl/100 µl CD271hu-
PerCP/Cy5.5 (NGFR) antibody for 30 min at 4 °C.  
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B muCD45 staining 
Bone marrow suspension (4.2.6 Isolation of PDX cells from mouse bone marrow) was diluted 
in PBS to a concentration of 4 x 108 cells/ml, stained 1:100 (v/v) with CD45mu-APC-Cy7 
antibody and incubated for 30 min at 4 °C.  
 
C 5-Bromo-2'-desoxyuridine (BrdU) staining 
The detection of BrdU incorporation was performed according to maufacturer’s instructions of 
the BrdU Flow Kit (3.6 Kits). 
 
D 4',6-diamidino-2-phenylindole (DAPI) staining 
To exclude dead cells 10 µg/ml DAPI was added to the cell suspension immediately prior to 
measurement.  
 
After incubation time cells were washed with PBS (400 g, 5 min, RT) and re-suspended in PBS 
to a final concentration of 107 cells/ml. 
Stained cells where analyzed by flow cytometry, using either a BD LSRFortessa or a BD 
FACSAriaIII (see 4.4.7 Flow cytometry analysis). 
4.4.7 Flow cytometry analysis 
Flow cytometry analyses were performed using a BD LSRFortessa, a BD FACSAriaIII, or a 
BD FACSCalibur. Fluorescent proteins (mKate, mCherry) and other fluorochromes (APC-Cy7, 
PerCP-Cy5.5, DAPI,) were measured using the laser and filter settings indicated in Table 4. 
PDX samples were gated for living cells in FSC/SSC and for respective fluorochromes.  
 
Table 4: Filter settings of flow cytometry 
Laser [nm] Longpass Filter [nm] Bandpass Filter [nm] Parameter 
LSRFortessa    
355 505 525/50 
450/50 
 
Indo-1 
DAPI 
405 595 
475 
605/12 
525/50 
450/50 
 
Qdot 605 
Qdot 525 
Pacific Blue 
488 600 695/40 PerCP-Cy5.5 
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505 530/30 
499/10 
 
FITC, CFSE 
SSC 
561 750 
685 
635 
600 
570 
 
780/60 
710/50 
670/30 
610/20 
585/15 
PE-Cy7 
PE-Cy5.5 
PE-Cy5 
mCherry 
PE 
640 750 
710 
 
780/60 
730/45 
670/14 
 
APC-Cy7 
Alexa Fluor 700 
APC-Cy7 
FACSAriaIII    
375/405 735 
610 
556 
502 
780/60 
616/23 
584//42 
530/30 
450/40 
 
Qdot710 
Qdot605 
PacOrange 
Cerulan 
DAPI 
488 655 
502 
 
695/40 
530/30 
488/10 
 
PerCP-Cy5.5 
FITC, CFSE 
SSC 
561 735 
630 
600 
780/60 
670/14 
610/20 
582/15 
 
PE-Cy7 
PE-Cy5 
mCherry, mKate 
PE 
633 735 780/60 
660/20 
 
APC-Cy7 
APC 
FACSCalibur    
488  488/10 
530/30 
585/42 
>670 
SSC 
FL1 FITC 
FL2 PE 
FL3 PerCP 
635  661/16 FL4 APC 
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4.5 Statistics 
Two-tailed unpaired t-test was applied to determine the significance of relative reduction rates 
upon drug stimulation. F-test was applied to compare variances and in cases in which variances 
differed significantly, Welch’s correction was employed. All statistical analyses were 
calculated using GraphPad Prism 6 software. 
LIC frequencies were calculated according to Poisson statistics using the ELDA software 
application (http://bioinf.wehi.edu.au/software/elda) (Hu and Smyth, 2009). 
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5 Results 
Drug resistant cells that survive treatment might induce relapse in acute leukemias (AL) patients 
and therefore represent a major obstacle for curing AL. It remains a major challenge to isolate 
high numbers of drug resistant cells directly from patients as these cells are very rare; therefore, 
data on the functional characteristics of these important cells does not exist in the literature. 
To overcome this obstacle, the patient-derived xenograft (PDX) model was used to study 
patients’ tumor cells in vivo (Kamel-Reid et al., 1989; Liem et al., 2004; Shultz et al., 2005). 
The aim was to identify, isolate and characterize drug resistant cells with relapse-inducing 
potential from patients’ AL samples, using their in vivo resting phenotype as anchor.  
The following result section is divided into three parts; first, the optimization and the 
establishment of two methods to isolate minute amounts of PDX cells out of mouse bone 
marrow is described. Second, data are presented which reveal the presence of long-term resting 
PDX cells in patient samples of diverse leukemia subtypes. Third and last, certain functional 
properties of long-term resting PDX cells are described. 
These results will help to understand relapse-inducing cells in more detail and to ultimately 
develop treatment strategies to target relapse-inducing cells for a better prognosis of AL 
patients. 
5.1 Pool of transfected AL samples 
The overall study on dormant ALL cells was started by Sebastian Tiedt who mainly worked 
with two high risk relapse samples ALL-199 and ALL-265 (Tiedt, 2014). Therefore the current 
work was started by establishing a broader pool of PDX AL cells with the aim to be more 
representative for the heterogeneity within AL. Cells from different patients, with different AL 
subtypes and at different stages of disease were chosen for the experiments. Table 6 and Table 
5 show the five AML and the four ALL PDX samples that were used for the main experiments 
within this study. Information on all further samples that were used in this study is shown in 
Table S 2 and Table S 1. 
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Table 5: Clinical data of AML patients and sample characteristics of AML PDX samples used for main 
experiments. 
 
 
The passaging time in mice, defined as the days from injection of around 107 cells per mouse 
until mice had to be sacrificed due to end stage leukemia, was between 30 and 130 days with 
an average of 66 days for AML and 59 days for ALL samples. Furthermore and for time saving 
reasons, all but one sample had passaging times below 50 days limiting the aim to represent the 
heterogeneity of AL. 
For the main experiments in AML, samples expressed mCherry and luciferase were used to 
facilitate enrichment from mouse bone marrow. The transgenes had already been expressed in 
the PDX cells by other laboratory group members before. For the main experiments in ALL, 
samples expressing mCherry, luciferase and/or NGFR were used. mCherry transfection was 
performed for these samples within this study.  
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Table 6: Clinical data of ALL patients and sample characteristics of ALL PDX samples used for main 
experiments. 
 
 
5.2 Isolation of minute numbers of PDX cells from mouse bone marrow 
Minute numbers of treatment resistant cells might be responsible for relapse in patients. To 
improve treatment and prognosis of patients, investigations on these cells are necessary, but 
technical limitation hampered functional characterization of these challenging cells so far. The 
present study used the PDX AL model and concentrated on the first 3 weeks of AL growth in 
mice. Here, the low tumor burden is mainly restricted to bone marrow without major 
involvement of further organs (Barrett et al., 2011; Bomken et al., 2013) and reliable isolation, 
enrichment and detection of very low numbers of PDX cells from mouse bone marrow was 
necessary (Figure 5). 
When 107 ALL-199 PDX cells were injected into two mice and re-isolated after two or 42 days 
from mouse bone marrow, huge differences in the number of PDX cells became visible. After 
two days, human cells were measured which had successfully homed to the bone marrow which 
were only a 0.21 % of all living mononuclear cells in mouse bone marrow after transplantation 
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of ALL-199, whereas after 42 days 91.6 % of all living mononuclear cells in mouse bone 
marrow were human (Figure 5).  
 
 
Figure 5: Minute numbers of PDX cells exist at early time points in the mouse bone marrow  
Upper panel: original FACS data of mouse bone marrow cells, gated on the living lymphocyte population (DAPI-
) two and 42 days after injection of 107 ALL-199 PDX cells. Lower panel: scheme indicating that at early time 
points after injection of AL PDX only minute numbers of human PDX can be detected in the mouse bone marrow, 
whereas full blown leukemia consist of nearly 100 % human PDX cells in mouse bone marrow. 
 
For isolation and enrichment of low numbers of PDX cells from mouse bone marrow, cells 
transgenic for NGFR and a fluorochrome were used in the enrichment method established by 
Sebastian Tiedt (Tiedt, 2014). 
Transgenes allowed the effective enrichment of PDX cells from mouse bone marrow in a 
twostep procedure. A first enrichment step consisted in magnetic cell separation (MACS) of 
NGFR-expressing PDX ALL cells from the entire mouse bone marrow isolated. The second 
consecutive enrichment step consisted in flow cytometry enrichment of red fluorescent protein 
mKate expressing cells out of the cell suspension obtained after MACS enrichment. Here cells 
obtained after MACS enrichment were stained with DAPI to exclude dead cells and with anti-
muCD45 antibody to exclude mouse hematopoietic cells (see 4.2.7 Enrichment of PDX cells 
by magnetic cell separation (MACS) and 4.2.8 Enrichment of PDX cells by fluorescence-
activated cell sorting (FACS)). 
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Within this work the NGFR MACS FACS procedure was optimized to save time and material. 
As the red fluorescent protein mKate used by Sebastian Tiedt was not bright enough to clearly 
discriminate between transfected and non-transfected cells, cells were transfected with 
mCherry, as this fluorochrome has higher mean fluorescent intensity (MFI) (Figure 6). 
 
 
Figure 6: The red fluorescent protein mCherry has higher MFI than the red fluorescent protein mKate 
107 ALL-199 PDX cells expressing mKate or mCherry were injected i.v. into mice, and after 10 days re-isolated 
from mouse bone marrow and analyzed for red fluorescent color. 
 
For mKate alone it was not possible to clearly separate the positive PDX population from the 
negative mouse population by FACS. PDX cells expressing mCherry could be reliably 
identified in flow cytometry, and no additional anti-muCD45 staining was necessary to 
discriminate human from mouse cells (Figure 6). In addition, a titration of the magnetic anti-
NGFR beads was performed, to reduce cost. 4x108 whole bone marrow cells isolated from 
leukemia-free NSG mice were mixed with 8x105 ALL-199 PDX cells expressing mCherry and 
NGFR, and with different amounts of magnetic anti-NGFR beads. As highest amount of beads 
the company instruction (800µl) was used. For titration steps different amounts of beads until 
1/80 of company instructions (10µl) were added to the cell suspension. 
Afterwards MACS-based enrichment was performed on the mixtures, and collected cells were 
measured and quantified by flow cytometry gating (i) on the lymphocyte gate in forward/side 
scatter and (ii) the gate negative for DAPI and positive for mCherry (Figure 7). 
The graph in Figure 7 shows clearly that no cell loss was obtained if at least 100 µl of beads 
were used. When less beads were used the amount of isolated PDX cells decreased. To avoid 
cell loss during the enrichment steps, 200 µl of anti-NGFR beads were used for all further 
experiments. By reducing the amount of required beads by factor 4, the cost for beads could be 
reduced by factor 4 and thus substantially. 
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Figure 7: Optimization of NGFR MACS procedure 
4x108 mouse bone marrow cells were mixed with 8x105 ALL-199 PDX cells expressing mCherry and different 
amounts of magnetic anti-NGFR beads; MACS-based enrichment by NGFR was performed and collected cells 
were measured by flow cytometry. Total amount of mCherry positive cells was quantified by flow cytometry. 
 
As a second approach and to spare the second lentiviral transduction step for the expression of 
recombinant NGFR, a MACS based enrichment method which was independent of NGFR 
expression and instead used a newly commercially available so called “mouse cell depletion 
kit, which came on the market 2014. Here mouse cells from the bone marrow were captured by 
a commercial available mix of mouse antibody beads. During magnetic separation labeled 
mouse cells are captured in the columns and unlabeled cells were directly collected (Agorku et 
al., 2014). After this altered MACS enrichment step 1, further enrichment was performed by 
flow cytometry targeting on the transgenic mCherry identically as described above. To establish 
this enrichment method, the required amount of mouse cell depletion beads were determined 
by titration: 4x108 mouse bone marrow cells were mixed with 8x105 mCherry expressing PDX 
cells and different amounts of magnetic beads. Theoretically, if lower amounts of beads are 
used, lower amounts of mouse cells are captured and therefore the negative fraction including 
the human PDX cells would increase. Therefore here the read out was the measurement time at 
the flow cytometer for the negative fraction. To perform experiments with four mice on one 
day, measurement time of one mouse should not exceed one hour (Table 7).  
Table 7 shows that all tested amounts of beads lead to measurement times below one hour. To 
save material the lowest amount of beads (100µl) was used for all further experiments. 
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Table 7: Optimization of mouse cell depletion MACS to enrich minute numbers of PDX cells from mouse 
bone marrow cells 
 
 
Next, the mouse cell depletion method was validated, to ensure that it can isolate minute 
numbers of PDX cells from mouse bone marrow. Different numbers of mCherry expressing 
PDX cells were mixed with mouse bone marrow cells followed by the new enrichment 
procedure to quantify recovered PDX cell (Table 8).  
 
Table 8: Twostep procedure with mouse cell depletion MACS allows enrichment of minute numbers of PDX 
cells from mouse bone marrow 
 
 
A mouse bone marrow from a mouse without injected or mixed in PDX cells only showed 6 
false positive events in the DAPI- mCherry+ population. This background amount was always 
subtracted from all measured mCherry positive PDX samples to determine the absolute amount 
of PDX cells. Using the new enrichment protocol, as few as 174 PDX cells could be re-isolated 
out of 2x108 normal mouse bone marrow cells and therefore enabled cell enrichment of a factor 
well above 106 with little cell losses. This enrichment procedure could reliably be used for 
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further experiments to detect and isolate very few PDX cells in mouse bone marrow. The two 
enrichment protocols will referred to as NGFR MACS and MCD (mouse cell depletion) MACS 
throughout the text. 
 
Next both enrichment techniques were compared to ensure that they do enrich and isolated PDX 
cells from mouse bone marrow with similar efficiency. 1x108 mouse bone marrow cells were 
mixed with 4.2x104 mCherry and NGFR expressing PDX cells. Duplicates were either enriched 
by NGFR MACS or by MCD MACS and total amount of PDX cells were determined using 
flow cytometry targeting mCherry expressing cells (Table 9).  
 
Table 9: MCD MACS can substitute NGFR MACS 
 
 
Table 9 shows that both methods can recover between 67 % and 81 % of added PDX cells. 
Therefore, MCD MACS was used for all further experiments in NGFR negative PDX samples.  
Taken together, two different techniques to isolate minute numbers of transgenic PDX cells 
from mouse bone marrow were established or optimized and serve as basis for further isolation 
and characterization of challenging subpopulations in AL. 
5.3 Growth behavior of PDX cells in mice 
The established procedures enabled addressing basic questions with translational potential in 
AL biology. Investigations on leukemia biology were performed at diagnosis, meaning at late 
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time points of the disease, during treatment process or at relapse (De Kouchkovsky and Abdul-
Hay, 2016; Pui et al., 2015). Investigations on early leukemia development are missing. As a 
consequence little is known about the growth of leukemia in patients. But knowledge about the 
early growth, detailed kinetic and relapse of the leukemia would increase the understanding of 
the disease and would help to improve or develop new treatment strategies. Therefore, the in 
vivo growth behavior of different AL samples in mouse bone marrow was studied regarding 
homing and spontaneous growth. 
5.3.1 Homing of PDX samples to mouse bone marrow 
Homing is the process in which cells, systemically injected into the blood stream of animals, 
travel to their most appropriate niche. This process, intensively studied in normal 
hematopoiesis, elucidates rolling, adhesion, migration and the tumor-stroma interaction. As the 
hosting laboratory had reproduced that the bone marrow is the first site of homing for PDX AL 
cells in NSG mice (Terziyska et al., 2012; Vick et al., 2015), here the homing to mouse bone 
marrow was studied. 
 
107 fresh ALL or AML cells from mice with advanced leukemia sacrificed on the same day 
were injected into the tail veins of next recipient mice and re-isolated three days later by 
applying one of the established enrichment methods. The time point of three days was chosen 
as the current study could show that cells did not proliferate within the first three days (see 
below Figure 13 and Figure 18), while removal of non-homed cells by the mouse phagocyte 
system should be completed by then. 
In samples that did not express any transgenes, an alternative protocol was used; PDX AL cells 
were stained with CFSE (see 4.4.5 5-(6)-Carboxyfluorescein-Succinimidyl Ester (CFSE) 
staining of cells) before injection and analyzed directly by flow cytometry for CFSE positive 
cells. As cells could not be enriched by NGFR MACS prior to FACS analysis and FACS 
analysis was unfeasible for larger cell numbers, a portion of the bone marrow suspension was 
directly analyzed and absolute numbers of PDX cells were calculated thereof (Figure 8). 
However, after the MCD kit had been established this drawback was solved and mouse cells 
were removed by MACS before FACS measurement for samples not expressing transgenes 
(Agorku et al., 2014). 
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Figure 8: PDX samples differ broadly in their homing capacity to mouse bone marrow 
107 AML (A) or ALL (B) PDX cells were injected i.v. into mice and re-isolated from the bone marrow three days 
later, and absolute cell number was measured; each dot represents data from one mouse, except that a mean of six 
mice plus standard error is shown for samples ALL-199 and ALL-265 and mean of up to three mice plus standard 
error is shown for samples AML-491, AML-372, AML-393, and AML-346. 
 
Homing of 19 different PDX AL samples was measured and a maximum of 4 % of the injected 
PDX cells could be re-isolated from mouse bone marrow three days after injection (Figure 8). 
The eight different ALL samples and eleven AML samples showed highly different cell 
recruitment to bone marrow differing by more than two orders of magnitude with a minimum 
efficiency of only 0.01 % of injected cells homing to bone marrow in AML-388 and a maximum 
of 1.05 % in AML-491.  
 
These data indicate that homing of fresh PDX AL samples to mouse bone marrow is an overall 
highly inefficient process, but similar between ALL and AML. Differences between the 
samples suggest that homing might depend on specific, yet undefined characteristics of 
individual samples. 
 
Next, it was studied how the number of injected PDX cells might influence homing. Between 
107 and 105 ALL-199 cells were injected i.v. into mice and re-isolated by NGFR MACS three 
days later (Figure 9). A maximum 107 cells were chosen for injection, as former experiments in 
the laboratory showed that injection of more than 107 cells lead to severe agglutination in mice. 
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Figure 9: Homing to mouse bone marrow depends on the cell number injected 
ALL-199 cells were injected i.v. into mice at different cell numbers and re-isolated by NGFR MACS after three 
days; each dot indicates data from one animal. 
A Absolute number of homed PDX cells. 
B Percentage of homed PDX cells. 
 
The homing capacity into the mouse bone marrow strictly depended on the cell numbers 
injected. Surprisingly, when higher cell numbers were injected, homing efficiency increased. 
Injection of 107 cell lead to homing of 1.2 % of the injected cells, whereas the injection of 105 
cells lead to a homing of 0.03 % of cells (Figure 9B).  
To work with a maximum number of homed PDX AL cells per sample, 107 freshly isolated 
cells/mouse were injected in all further experiments.  
 
These data argue against the existence of a preformed, fixed number of niche places present in 
the bone marrow of each NSG mouse, which are able to house PDX cells. These data strengthen 
the assumption, that specific characteristics of the individual leukemia sample and the cell 
number injected determine the ability of the cells to home to bone marrow.  
5.3.2 In vivo growth of PDX cells in mouse bone marrow over time 
For a more detailed knowledge about the growth of leukemia, the in vivo growth of PDX cells 
in mice was studied over time. Therefore, 107 PDX cells were injected i.v. into mice and 
followed by quantifying absolute numbers (Figure 10) or relative amount (Figure 11) of PDX 
cells in mouse bone marrow at different time upon ex vivo cell enrichments. 
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Figure 10: Growth curves of AML-PDX cells in vivo show early logarithmic growth in mouse bone marrow 
107 CFSE stained PDX cells were injected i.v. at different time points up to five mice were analyzed and PDX 
cells were quantified; shown is mean +/- standard error. 
 
 
Figure 11: Percentage of PDX in bone marrow shows early logarithmic growth in mouse bone marrow  
107 ALL-199 PDX cells were injected i.v. At different time points 10 % of mouse bone marrow was analyzed and 
percentage of PDX cells was calculated. 
 
The growth of PDX AL cells in mouse bone marrow was logarithmic over the first weeks of in 
vivo growth, and growth slowed down thereafter when PDX cells reached only 10 % of total 
cells in mouse bone marrow. This growth behavior is called logistic growth (Araujo and 
McElwain, 2004; Schacht, 1980) and the same results had also been obtained for absolute 
numbers of ALL samples (Tiedt, 2014). 
 
From samples which were isolated at least at three different time points, absolute PDX numbers 
were determined and doubling times were calculated thereof (see 4.2.10 Calculation of cell 
number doubling times in vivo) (Figure 12). 
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Figure 12: AML PDX samples differ broadly in their doubling times in vivo 
107 AML PDX cells were injected i.v. into at least three mice and re-isolated from the bone marrow at different 
time points. From absolute numbers of re-isolated PDX cells doubling time in days per sample was calculated.  
 
Doubling times were analyzed in eight different AML PDX samples and varied widely. The 
shortest time for a single duplication was one day, whereas the maximum time was 3.5 days in 
the eight samples studied. 
 
Taken together new insights about leukemic growth were gained. PDX AL cells show sample-
specific homing and doubling times followed by early logistic growth in mouse bone marrow. 
5.4 A rare long-term dormant subpopulation exists in PDX cells 
Surviving malignant cells after therapy are a major obstacle in the cure of ALL and AML as 
they might induce deadly relapse (Blatter and Rottenberg, 2015; Gokbuget et al., 2012b; 
Ommen, 2016). A reason for therapy resistant cells might be their dormant state (Aguirre-
Ghiso, 2007; Essers and Trumpp, 2010; Schillert et al., 2013). The hosting laboratory decided 
using long-term dormancy as an anchor to get their hands onto relapse-inducing cells before 
this study started. Towards this aim, Sebastian Tiedt had established a method using the 
proliferation-sensitive dye 5-(6)-Carboxyfluorescein-Succinimidyl Ester (CFSE) which had 
already been used in mouse model studies on healthy hematopoiesis or AML, e.g., to 
characterize heterogeneous growth pattern and to identify dormant HSC (Takizawa et al., 2011; 
van der Wath et al., 2009). Sebastian Tiedt adapted the use of CFSE to studies on PDX ALL 
cells. Using three different samples, Sebastian Tiedt found for the first time that a rare 
subpopulation of long-term dormant cells exists in PDX ALL (Tiedt, 2014). The present work 
aimed next at broadening the existing data and studied additional PDX ALL samples for the 
existence of the long-term dormant subpopulation, including further ALL subtypes and PDX 
AML samples.  
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5.4.1 Establishing CFSE staining to follow up PDX AML proliferation in vivo 
With the aim of optimizing the established protocol from Sebastian Tiedt and transferring it to 
PDX AML, 107 AML-491 cells were stained ex vivo with CFSE (see 4.4.5 5-(6)-
Carboxyfluorescein-Succinimidyl Ester (CFSE) staining of cells) and were re-injected into next 
recipient mice. After 2, 10 and 16 days mouse bone marrow was collected from one mouse per 
time point and PDX cells were enriched by MCD MACS. Afterwards, PDX cells were analyzed 
targeting transgenic mCherry and the green CFSE dye to follow up proliferation in flow 
cytometry (Figure 13). 
 
 
Figure 13: Loss of CFSE signal over time  
107 AML-491 cells were injected into 3 mice and re-isolated by MCD MACS and analyzed by flow cytometry for 
the green CFSE dye at day 2, 10, and 14 after cell injection. 
 
Two days after cell injection, all PDX cells in the mouse bone marrow were still CFSE positive. 
At later time points cells were slowly losing their CFSE label. The CFSE MFI was drifting from 
right to left. The distribution of the CFSE signal at later time points was broad, showing that 
not all cells participated identically in proliferation (Figure 13).  
 
As BrdU incorporation is commonly used as proliferation marker and might be considered as 
“gold standard” to measure proliferation, CFSE labeling was validated as readout for measuring 
in vivo proliferation using a parallel BrdU staining (Figure 14). 
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Figure 14: Loss of CFSE correlates with loss of BrdU 
Donor mouse engrafted with ALL-265 was fed with drinking water containing BrdU (0.8 mg/ml) within the last 
seven days before cell harvesting. After re-isolation 107 cells were stained ex vivo with CFSE and were injected 
into four recipient mice. At days 1, 7, 10 and 17 mice were sscrified and PDX cells were isolated and quantified. 
“BrdU-ab” indicates that cells were stained with the anti-BrdU antibody; “+” and “-” indicate that the procedures 
were performed or not, respectively.  
A Raw FACS data of three time points for BrdU and CFSE stainings.  
B Correlation of BrdU positive and CFSE positive cells. Each dot represents data from one mouse. 
C Exemplary FACS blots of control cells which were negative for BrdU and CFSE but stained with the BrdU 
antibody. 
 
To stain leukemia cells with BrdU, a donor mouse was fed with BrdU the last 7 days before 
mice had to be taken down due to advanced leukemia. All leukemia cells re-isolated from the 
mouse spleen were BrdU positive, indicating strong proliferation in spleen at late time points. 
These cells were then stained ex vivo with CFSE, and 107 CFSE+ and BrdU+ PDX cells were 
injected i.v. into four mice. At different time points, mice were taken down and PDX cells were 
isolated and analyzed concerning BrdU and CFSE intensity. One day after cell isolation BrdU 
and CFSE signal are high. 7 and 17 days after cell injection both dyes lost the same amount of 
signal and the cell population is shifting from the right upper corner towards the left lower 
corner. The BrdU signal was from beginning on more egg shaped, most probably due to 
different BrdU take of in the donor mice before, and stays egg shaped for all time points (Figure 
14A). When CFSE and BrdU negative control cells were stained with BrdU antibody, the cell 
population was still negative for both signals, indicating no false positive staining by the 
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antibody (Figure 14C). Graphical analysis of the BrdU and CFSE MFI shows tight correlation 
of the loss of CFSE with the loss of BrdU signal (Figure 14B). Therefore CFSE can substitute 
BrdU as proliferation marker for further experiments. 
 
As additional quality control, loss of CFSE signal was correlated with cell quantity upon cell 
isolation (Figure 15). 
 
 
Figure 15: Loss of CFSE correlates to gain in cell numbers  
107 CFSE stained PDX AML-491 cells were injected i.v. into mice and PDX cells were re-isolated and quantified 
from the bone marrow after 2, 4, 7, 10, 14, 16 and 21 days; each dot represents data from one mouse. 
 
Here 107 CFSE stained PDX cells were injected i.v. into seven mice. PDX cells were re-isolated 
at different time points from day two on, quantified and analyzed for CFSE content. Figure 15 
shows that increase in PDX cell numbers closely correlated with loss of CFSE signal. 
 
As loss of CFSE staining closely correlates with both loss of BrdU staining and increase in 
absolute cell numbers, CFSE staining represents a reliable approach to monitor proliferation of 
PDX AML and ALL cells in mice. 
5.4.2 Analyzing CFSE staining to detect dormant cells 
Next, loss of CFSE was used to distinguish subpopulations of slowly and rapidly growing cells 
in AML and ALL. Therefore, gates for slowly and rapidly growing cells were defined as 
established by Sebastian Tiedt for ALL (Figure 16). 
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Figure 16: Gates defining label retaining cells (LRC) and non-label retaining cells (non-LRC) 
MFI of CFSE at start of the experiment (2 or 3 days after cell injection) was divided by factor 2 to model bisections; 
upon less than 3 bisections, cells were considered as LRC, upon more than 7 bisections as non-LRC; intermediate 
cells were considered as “others”. Shown are exemplary FACS blots with the calculated bisection lines of AML-
491 at day 2, 10, and 14 after cell injection. 
 
To set these gates and measure maximum CFSE mean fluorescence intensity (MFI), maximum 
CFSE intensity was measured at day 2 or 3 after injection. CFSE MFI was used to define start 
of any cell proliferation (“0 divisions”). CFSE bisections were calculated as surrogates for cell 
divisions by dividing CFSE MFI by factor 2. According to the use of the term in work on normal 
mouse hematopoiesis, cells were called label-retaining cells (LRC), if they had undergone less 
than 3 bisections of maximum CFSE MFI indicating dormant cells (Schillert et al., 2013). Cells 
that entirely lost CFSE and contained less CFSE than 7 bisections of maximum CFSE MFI 
were called non-LRC, indicating proliferating cells (Figure 16).  
 
 
Figure 17: Controls for enrichment method with MCD MACS and CFSE staining 
A MCD MACS was performed with a mouse bone marrow without prior application of PDX cells. Only six cells 
were detected in the mCherry gate but no cells in the LRC gate. 
B MCD MACS was performed with a femur of a fully engrafted mouse without prior CFSE labeling of AML-491 
PDX cells. No cells were found in the LRC gate. 
 
Additional quality controls were performed and background green fluorescence after MCD 
MACS in (i) a mouse with advanced leukemia containing PDX cells never labeled with CFSE; 
and (ii) a mouse which never received PDX cells were determined (Figure 17). 
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In both controls, no cells were found in the LRC gate, indicating that all cells that are detected 
in the LRC gate during experiments truly derive from CFSE labeled PDX AL cells. 
 
For each in vivo experiment a day 2 or day 3 mouse was required as control to set the LRC gate. 
To save resources, it was tested if CFSE stained PDX cells cultured ex vivo could be used for 
the LRC gate settings (Figure 18). 
 
 
Figure 18: CFSE stained cells have similar MFI after 2 days in vivo and ex vivo consequently giving raise to 
same LRC and non-LRC gates  
107 CFSE stained AML-491 or AML-372 PDX cells were injected i.v. into one mouse and re-isolated from the 
bone marrow 2 days later (left panel); 106 CFSE stained AML-491 or AML-372 PDX cells were cultured ex vivo 
for 2 days (middle panel); CFSE MFI signals of in vivo and ex vivo cultured PDX cells were compared by histogram 
(right panel). 
 
For two different samples, 107 CFSE stained PDX cells were injected into one mouse and 
re-isolated and analyzed 2 days later. In parallel 106 CFSE stained PDX cells were cultured ex 
vivo for 2 days (see 4.4.4 Ex vivo culture of PDX cells). For both approaches CFSE MFI was 
determined and LRC and non-LRC gates were calculated thereof. As shown in Figure 18, CFSE 
MFI for both approaches and in both samples was similar and therefore gave rise to the same 
LRC and non-LRC gates. Thus, in further experiments, CFSE stained PDX cells cultured ex 
vivo for 2 or 3 days were used to set LRC gate.  
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In summary, as Sebastian Tiedt established before for ALL, CFSE labeling and analyzing was 
established to study PDX AML proliferation in vivo. To set gates for fast and slowly 
proliferating cells ex vivo control were established and different controls showed that cells in 
the slowly proliferating LRC gate truly come from CFSE positive AL cells. 
5.4.3 All except one PDX AML samples contain a rare dormant subpopulation 
As Sebastian Tiedt detected for the first time long-term dormant cells in ALL (Tiedt, 2014), the 
next aim was to investigate the proliferation pattern of AML PDX cells in vivo. With the CFSE 
labeling, PDX enrichment, and analysis methods established above, multiple AML PDX 
samples from different AML subgroups were studied for their growth in vivo. First CFSE 
kinetics for three different AML samples were performed to study the in vivo proliferation 
pattern of AML PDX samples over time (Figure 19).  
For each AML sample 107 CFSE stained cells were injected into 6-7 mice and re-isolated 
between day 2 or 3 and day 21 or 29. At each time point one mouse was taken down, enriched 
for PDX cells and analyzed for CFSE content. Figure 19 shows, that all three analyzed AML 
samples lost CFSE content over time, indicating cell proliferation. In all three samples the PDX 
population did not lose the CFSE dye homogenously, instead some cells still retained the label 
even at late time points. Thus, all samples analyzed grow heterogeneously in mice and contain 
a rare subpopulation of dormant LRC. 
 
To exclude that LRC are restricted to these three individual AML samples and to understand 
whether also other subgroups of AML contain long-term dormant cells, six additional AML 
samples were analyzed for the existence of the LRC population (Figure 20 and Figure 21). To 
represent the heterogeneity of AML, samples from adults and children, samples from primary 
disease and from first or second relapse, from different ELN classifications, and samples with 
and without genetic engineering were tested. As before 107 CFSE stained PDX cells were 
injected i.v. per mouse and re-isolated and analyzed for CFSE content after 14 days. 
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Figure 19: AML PDX samples grow heterogeneously in mice over time  
107 CFSE stained AML PDX cells were injected i.v. into 6-7 mice; PDX cells were enriched from 1 mouse at each 
time point and analyzed by flow cytometry for CFSE content. One representative kinetics out of two identical 
experiments is shown for each sample. 
 
 
Figure 20: A rare, long-term dormant subpopulation exists in different subtypes of AML PDX cells growing 
in mice 
PDX cells from eight AML patients were studied, including different ELN classifications, pediatric and adult 
samples, samples from initial diagnosis and from relapse, and samples with and without genetic engineering. 107 
CFSE stained PDX cells were injected i.v. per mouse and were analyzed after 14 days. AML-538, AML-356 and 
AML-358 were not genetically engineered. Here, 10 % of the entire bone marrow isolate was analyzed without a 
prior MACS enrichment step. LRC numbers are indicated. 
 
5 out of 6 of the additionally studied AML samples and 8 out of 9 of all studied PDX AML 
samples contained the rare subpopulation of LRC (Figure 20), suggesting that existence of long-
term resting cells is a frequent phenotype in AML across different AML subtypes and 
characteristics. Interestingly, one PDX AML sample, AML-346 did not show long-term resting 
cells (Figure 21). To exclude that the absence of LRC in this sample was a measurement or 
staining error, this sample was analyzed several times for LRC (Figure 21). 
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Figure 21: AML-346 has no dormant subpopulation of LRC 
107 CFSE stained PDX cells were injected i.v. per mouse and were analyzed at indicated time points; PDX cells 
were enriched by MCD MACS and analyzed by flow cytometry. LRC numbers are indicated. 
 
For AML-346 three times day 7 and once day 15 was analyzed. Mainly all cells lost the CFSE 
dye already after 7 days. Thus in AML-346 all cells participate to proliferation, and no dormant 
subpopulation was present. This sample was derived from a child with a high risk relapse. The 
tumor behaved highly aggressive in the patient and the patient died of the disease (Table S 1). 
Absence of LRC in this sample suggests that LRC are not associated with aggressiveness in 
patients.  
 
In summary, it was shown that similarity to ALL most AML samples grow heterogeneously in 
mice and that 8 out of 9 PDX AML samples contain the rare dormant subpopulation of LRC.  
5.4.4 Different subtypes of ALL contain a dormant subpopulation 
In ALL, Sebastian Tiedt started to study PDX samples for their growth pattern in mice and first 
described the existence of LRC. But as he only studied three ALL samples (Tiedt, 2014), these 
experiments were verified and pursued.  
 
Different subtypes of ALL were studied for the existence of LRC. In total, eight PDX ALL 
samples were studied, which included B-cell precursor-ALL and T-ALL, pediatric and adult 
samples, samples from primary disease and from relapse and samples with and without genetic 
engineering (Figure 22). 
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Figure 22: A rare, long-term dormant subpopulation exists in different subtypes of ALL PDX cells growing 
in mice 
PDX cells from all eight ALL patients were studied, including B-cell precursor (BCP) ALL and T-ALL, pediatric 
and adult samples, samples from primary diseases and from relapse and samples with and without genetic 
engineering. Only ALL-199 and ALL-265 were genetically engineered. 107 CFSE stained PDX cells were injected 
i.v. per mouse and 10 % of bone marrow were analyzed at indicated time points. LRC numbers are indicated and 
grey indicates human non-LRC and mouse cells. 
 
For each sample 107 CFSE stained PDX ALL cells were injected i.v. and analyzed for CFSE 
content at indicated time points. For these experiments only samples ALL-199 and ALL-265 
expressed transgenes, all other samples were not genetically engineered to exclude that 
transgenes were responsible for the presence of LRC. Here 10 % of the entire population of 
bone marrow cells was directly analyzed by flow cytometry without prior MACS enrichment. 
To take into account the highly different proliferation rates and passaging times (Table 6) and 
with the aim to study late time points during passaging, most samples were analyzed when ⅓ – 
½ of passaging time in mice has passed. Even at these late time points, all samples contained 
cells in the LRC gate, indicating that these cells did not substantially divide, while overall 
leukemic load had increased by three orders of magnitude.  
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Thus, CFSE staining disclosed that in all eight PDX ALL samples studied not all PDX ALL 
cells participate equally in leukemia proliferation, instead a rare subpopulation of LRC that 
hardly divided over prolonged periods of time exists. 
 
In summary in AML and ALL PDX cells growing in mice a rare subpopulation of dormant cells 
was detected. These cells might be a surrogate for challenging leukemic cells in patients, which 
survive treatment and induce relapse with poor outcome. 
5.5 LRC are not enriched for cancer stem cells 
As long-term dormancy represents a hallmark of stem cells (Morrison and Spradling, 2008), it 
was analyzed, whether the dormant LRC were enriched for leukemia initiating cells (LIC) as 
stem cell surrogates. In ALL, Sebastian Tiedt already showed that ALL LRC are not enriched 
for stem cells (Tiedt, 2014). But as AML is the prototypic stem cell disease but AML stem cells 
remain difficult to enrich (Bonnet and Dick, 1997; Sarry et al., 2011), it was asked whether the 
subpopulation of LRC is enriched for cancer stem cells in AML. 
 
Using limiting dilution transplantation assays (LDTA) as gold standard method for determining 
LIC frequency (Castro Alves et al., 2012; Dick and Lapidot, 2005; Eppert et al., 2011; Sarry et 
al., 2011), FACS sorted LRC and non-LRC were re-transplanted into groups of mice after serial 
dilution. To monitor positive engraftment as read-out for the presence of LIC, in vivo imaging 
(see 4.2.11 Bioluminescence in vivo imaging) and blood measurement (see 4.2.3 Flow 
cytometry of human cells in mouse peripheral blood) were performed repetitively (Figure 23, 
Table S 3). 
Experiments were performed using AML samples AML-393 and AML-491. Limiting numbers 
of PDX cells were injected into groups of mice as indicated in Table S 3. Mice were counted 
as not engrafted when they did not show any sign of engraftment after twice the normal 
passaging time. LIC frequency was calculated using the online ELDA software 
(http://bioinf.wehi.edu.au/software/elda/) (Hu and Smyth, 2009). 
For AML-393, the calculated LIC frequency of non-LRC was 1/127 and for LRC 1/172. For 
AML-491, the calculated LIC frequency of non-LRC was 1/1364 and for LRC 1/853. Thus and 
for both samples, the LIC frequencies of non-LRC and LRC were highly similar if not identical 
indicating that stem cell frequencies were not increased in quiescent cells. 
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Figure 23: AML LRC are not enriched for stem cells 
LRC and non-LRC isolated and sorted of donor mice 10 days after injection of CFSE labeled AML-393 or AML-
491 cells were transplanted into secondary recipient mice in limiting dilutions at numbers indicated in Table S 3; 
bioluminescence in vivo imaging, blood measurement or BM FACS staining was performed to determine 
engraftment. LIC frequency was calculated using the ELDA software. 
 
Thus, LRC and non-LRC exhibited similar leukemia-initiating potential in the two AML 
samples analyzed, as it was already shown for ALL (Ebinger et al., 2016; Tiedt, 2014). 
Consequently LRC are not enriched for cancer stem cells. 
5.6 LRC survive systemic drug treatment in vivo 
In patients and as major challenge, drug resistant subpopulations of cancer cells might survive 
chemotherapy, persist over prolonged periods in the patients, and later might induce a relapse 
with poor prognosis (Gokbuget et al., 2012b; Locatelli et al., 2013; Lokody, 2014; Patel et al., 
2013). Especially dormant cells are known for their resistance against treatment with classical 
cytotoxic drugs, complicating elimination by anti-cancer therapy (Essers and Trumpp, 2010). 
As a rare dormant subpopulation was identified in PDX AL cells, the next question was whether 
this subpopulation behaves differently towards chemotherapy treatment compared to the bulk 
of leukemia cells. As a clinically related model, in vivo treatment of mice harboring PDX cells 
with cytotoxic drugs was performed and the different subpopulations were analyzed separately 
(Figure 24). 
For in vivo drug treatment experiments, 107 CFSE stained PDX cells were injected. After seven 
days of leukemic growth, mice were treated either with buffer as control or with cytotoxic drugs 
in a single or multiple applications. Mice were sacrificed at day 10 and PDX cells were re-
isolated and analyzed. As proof for stemness, drug resistant LRC of certain ALL samples were 
re-injected into next recipient mice (Figure 24).  
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Figure 24: Experimental procedure for drug treatment in vivo 
Mice were injected with 107 CFSE stained PDX cells. From day seven on mice received either buffer as control 
or a cytotoxic drug in a single or daily application. On day ten, mice were sacrificed and PDX cells were analyzed 
concerning their resting phenotype. Isolated LRC were re-transplanted as stem cell proof. 
5.6.1 Most AML LRC display increased drug resistance in vivo 
In patients, standard treatment of AML consists in cycles of an anthracycline for three days 
together with cytarabine for seven days. But cells might survive this treatment and later be 
responsible for relapse (De Kouchkovsky and Abdul-Hay, 2016; Estey and Dohner, 2006; Patel 
et al., 2013).  
To analyze whether dormant AML LRC are more drug resistant than proliferating cells, four 
AML samples AML-372, AML-393, AML-388 and AML-491 were studied as indicated in 
Figure 24. To mimic standard chemotherapy of AML patients, a treatment combination of the 
anthracycline DaunoXome and cytarabine was used. Concentrations were calculated from 
human dose to mouse equivalent dose (see 4.2.12 In vivo treatment of mice).  
In mice bearing AML-372, AML-393 and AML-388, the combination treatment markedly 
reduced leukemic load (Figure 25). 
To follow up leukemia load and treatment response, mice were imaged before and after 
treatment. At start of treatment at day seven, all mice had identical leukemia load. When mice 
were sacrificed, control mice show a slight increase in leukemia load, whereas drug treated 
mice had a clearly reduced tumor load in imaging by around one log (Figure 25A). Isolation 
and quantification of PDX AML cells showed an average reduction of 90 % of the tumor for 
AML-372 and AML-393, and even a 99.9 % reduction for AML-388 (Figure 25B). 
However, when dormant and proliferating subpopulations of AML-372, AML-393 and 
AML-388 were analyzed separately, marked difference became visible (Figure 26). 
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Figure 25: In vivo drug treatment reduced leukemic load in mice 
Mice were injected with 107 CFSE stained AML PDX cells. On day seven mice were treated either with buffer 
(ctrl) or with a single application DaunoXome (DNX 20 mg/kg i.p.) and a daily application of cytarabine (ARA-
C, 150 mg/kg i.p.). On day 10, mice were sacrificed and PDX cells were determined. 
A Treatment response in AML-393 and AML-388 bearing mice was monitored by in vivo imaging. 
B In vivo drug treatment reduced absolute numbers of living PDX cells; mean +/- standard error (AML-372 ctrl 
n=4, DNX & ARA-C n=6; AML-393 ctrl n=2, DNX & ARA-C n=2; AML-388 ctrl n=3, DNX & ARA-C n=4). 
 
 
Figure 26: LRC survive systemic drug treatment in vivo 
Analyses were performed as outlined in Figure 25. 
A Shown are original FACS data of representative mice from sample AML-372. 
B Quantification in all mice per group depicted as mean of relative drug effects on LRC compared to proliferating 
cells (100 %) +/- standard error; **** p<0.0001 by two-tailed unpaired t-test. 
C Mean relative proportion of LRC of total PDX cells with and without treatment; mean +/- standard error. 
* p<0.05, ** p<0.01 by two-tailed unpaired t-test and for AML-372 including Welch’s correction. 
 
Results  72 
 
 
 
FACS blots for two representative mice of control and treated AML-372 sample show that in 
the DNX & ARA-C-treated mouse, overall leukemic burden was decreased, while the LRC 
population remained nearly unchanged. In relative terms, the LRC subpopulation became even 
more prominent and increased in percentage of total leukemic load from 0.98 % in control mice 
to 8.13 % in treated mice (Figure 26A). In all three AML samples analyzed, proliferating cells 
were 10 to 100-fold more efficiently eliminated by in vivo drug treatment compared to LRC 
(Figure 26B). As a consequence, the relative percentage of LRC within the total population of 
cells increased significantly after treatment. For AML-372 and AML-388, percentage of LRC 
in total PDX population increased from 2 % in control mice up to 40 % in treated mice. For 
AML-393, the increase in percentage of LRC was not that prominent, but still significant as the 
percentage of LRC in total population increased from 0.7 % in control mice to 2.5 % in treated 
mice (Figure 26C).  
The forth studied sample, AML-491 behaved differently. AML-491 was shown in in vivo 
treatments trials before by Binje Vick in the hosting laboratory to be extremely sensitive 
towards three cycles of cytarabine application for four days. In LRC assays, AML-491 did not 
show major drug resistance of LRC (Figure 27). 
 
 
Figure 27: LRC of AML-491 do not show a clear drug resistance 
Mice were injected with 107 CFSE stained AML-491 PDX cells. On day seven mice were treated either with buffer 
(ctrl) or with a single application DaunoXome (DNX 1-20 mg/kg i.p.) and for three days with a daily application 
of cytarabine (ARA-C, 150 mg/kg i.p.). On day 10, mice were sacrificed and PDX cells were determined.  
A Absolute numbers of living PDX cells after in vivo drug treatment. Mean of n=2 for 20 mg/kg DNX & Ara-C 
+/- standard error. 
B Quantification in all mice per group depicted as mean of relative drug effects on LRC compared to non-LRC 
(100 %); mean of n=2 for 4 mg/kg DNX & Ara-C and n=2 for 20 mg/kg DNX & Ara-C +/- standard error; 
** p<0.01, by two-tailed unpaired t-test. 
C Mean relative proportion of LRC of total PDX cells with and without treatment. For 20 mg/kg DNX & Ara-C 
mean +/- standard error. 
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In AML-491, different concentrations of DaunoXome in combination with 150 mg/kg 
cytarabine were tested. All concentrations, but the lowest one, reduced tumor load by at least 
90 % (Figure 27A). However, if dormant LRC and proliferating cells were analyzed separately, 
it became obvious that also LRC were largely reduced by treatment of all concentrations. The 
reduction by treatment was a little less for LRC compared to proliferating cells, but AML-491 
LRC did not show major drug resistance compared to LRC of the other three AML samples 
studied (Figure 27B). This phenomenon became also obvious, by analyzing the relative 
percentage of LRC within the total population of cells isolated from treated mice, here only a 
slight increase of LRC after treatment became visible in AML-491 (Figure 27C). 
 
Taken together, in vivo treatment showed that in three of four AML samples analyzed, LRC are 
more drug resistant than non-LRC, indicating that dormancy might be a reason for the survival 
of malignant cells after chemotherapy treatment. 
5.6.2 ALL LRC are drug resistant in vivo 
In ALL, Sebastian Tiedt used two samples without technical or biological replicates to first 
describe that PDX ALL LRC were drug resistant (Tiedt, 2014). Here the task was to verify and 
pursue these experiments. 
 
First, the in vivo cytotoxic drug response in ALL-50 and ALL-435, two samples obtained from 
patients at initial diagnosis, was studied (Figure 28). 
The experiments were performed as described before (Figure 24). Routine ALL treatment in 
patients involves more different drugs compared to AML. In ALL and beyond the 
anthracyclines and purin-analogs used in AML patients, drugs like antimicrotubule agents and 
topoisomerase II inhibitors are used (Inaba et al., 2013; Pui et al., 2008). 
For ALL-50, mice were treated with either cytarabine, etoposide, amsacrine or epirubicine. For 
ALL-435, mice were treated with either etoposide, amsacrine or epirubicine. The in vivo 
imaging before and after treatment in ALL-50 showed increase of leukemic load in control mice 
and reduction of leukemic load after treatment by 1 log or more (Figure 28A). All PDX cells 
were re-isolated by MCD MACS and quantified in flow cytometry. Drug treatment with all 
drugs resulted in clear reduction of leukemic burden by over 90 % in both samples (Figure 
28B). The same experiment was performed with the two relapse samples ALL-199 and ALL-
265, to indicate that the results were not restricted to a certain disease stage (Figure 29).  
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Figure 28: LRC survive systemic drug treatment in vivo in ALL initial diagnosis samples 
Mice were injected with 107 CFSE stained ALL-50 or ALL-435 PDX cells. From day 7 on mice injected with 
ALL-50 received either buffer (ctrl), a daily application of cytarabine (ARA-C, 150 mg/kg i.p.; n=2), a daily 
application of etoposide (ETO, 33 mg/kg i.p.; n=2), a daily application of amsacrine (AMSA, 25 mg/kg i.p.; n=2) 
or a single application of epirubicine (EPI, 25 mg/kg i.p.; n=2). From day 7 on mice injected with ALL-435 
received either buffer (ctrl), ETO (33 mg/kg, i.p.; n=2), AMSA (25 mg/kg i.p.; n=2) or EPI (25 mg/kg i.p.; n=1). 
On day 10, mice were sacrificed and LRC were analyzed.  
A Treatment response in ALL-50 bearing mice was monitored by in vivo imaging. 
B In vivo drug treatment reduced absolute numbers of living PDX cells. 
C Quantification in all mice per group depicted as mean of relative drug effects on LRC compared to non-LRC 
(100 %) +/- standard error; ** p< 0.01, *** p<0.001, **** p<0.0001 by two-tailed unpaired t-test. 
D Mean relative proportion of LRC of total PDX cells with and without treatment +/- standard error. 
 
For ALL-199, single applications of etoposide or vincristine were used in 8-9 mice each; for 
ALL-265, single applications of etoposide or cyclophosphamide were used in 3-4 mice each. 
Similar to the experiments performed in AML, all cytotoxic drugs reduced overall leukemic 
burden by more than 90 % (Figure 29A). When drug response was evaluated separately for 
LRC and proliferating cells, a marked difference became visible. Proliferating cells were 
eliminated 10 to 100-fold more efficiently in vivo compared to LRC (Figure 28C and Figure 
29B). As a consequence, the relative percentage of LRC within the total population of cells 
increased after treatment (Figure 28D and Figure 29C). 
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Figure 29: LRC survive systemic drug treatment in vivo in ALL relapse samples. 
Mice were injected with 107 CFSE stained ALL-199 or ALL-265 PDX cells/mouse and received either buffer (ctrl, 
n=7 for ALL-199; n=3 for ALL-265), etoposide (ETO, 50 mg/kg, i.p.; n=8 for ALL-199; n=3 for ALL-265), 
vincristine (VCR, 1.5 mg/kg, i.v.; n=9 for ALL-199) or cyclophosphamide (CYCLO, 150 mg/kg, i.p.; n=4 for 
ALL-265) on day 7; on day 10, mice were sacrificed, LRC analyzed and re-transplanted into secondary recipients.  
A In vivo drug treatment reduced absolute numbers of living PDX cells. 
B Mean of all 3-9 mice per treatment, depicted as relative drug effect on LRC compared to non-LRC (100 %) +/- 
standard error; **** p<0.0001 by two-tailed unpaired t-test.  
C Mean relative proportion of LRC of total PDX cells with and without treatment +/- standard error. 
 
Thus, while ALL proliferating cells of four different samples were decreased by in vivo 
treatment by more than 1 order of magnitude, most ALL LRC survived chemotherapy, 
suggesting increased in vivo treatment resistance of LRC. Compared to AML, ALL LRC 
behaved more homogeneous, as all tested LRC were drug resistant. But it has to be considered 
that for both leukemia subtypes the sample size was low.  
5.6.3 ALL LRC have leukemia-initiating potential 
In patients, cells which survived chemotherapy treatment might be responsible for tumor 
relapse. Due to the cancer stem cell theory, tumors are hierarchically organized with cancer 
stem cells on top of the hierarchy. Only cancer stem cells are able to propagate and induce new 
tumors (Wang and Dick, 2005). Therefore it was studied whether drug resistant LRC have stem 
cell potential and were able to induce a new tumor by transplanting drug resistant LRC into 
next generation mice (Figure 30). 
Drug resistant LRC of ALL-199 and ALL-265 were isolated from bone marrow of treated mice 
and re-injected into next generation mice. Re-engraftment was followed by in vivo imaging (see 
4.2.11 Bioluminescence in vivo imaging). 
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Figure 30: LRC reveal stem cell potential. 
LRC from drug treated mice were isolated, re-transplanted, tumor growth was monitored by in vivo imaging, and 
bioluminescence signals were quantified. Imaging pictures from dpi 60 (ALL-199; ctrl; VCR), dpi 108 (ALL-199; 
ETO), dpi 67 (ALL-265; ctrl), dpi 78 (ALL-265; ETO) and dpi 73 (ALL-265; CYCLO) are shown. 
 
Upon re-transplantation, all drug resistant LRC harbored leukemia-initiating potential as they 
gave rise to new leukemia. Regarding proliferations kinetics, LRC after drug treatment induced 
leukemia at similar kinetics than untreated control LRC indicating that short term drug 
treatment did not induce changes in LRC (Figure 30).  
 
Thus ALL LRC have stem cell potential. They might represent surrogates for relapse-inducing 
cells in patients, as they can induce a new tumor after surviving treatment. 
 
Taken together, LRC share the most important functional features that impede to cure cancer 
in patients: (i) dormancy; (ii) in vivo drug resistance and; (iii) leukemia-initiating potential. 
LRC might thus serve as preclinical surrogate for relapse-inducing cells in ALL and AML.  
5.7 Release from environment induces proliferation in LRC 
A treatment option to target relapse-inducing, drug resistant and dormant cells might be the 
conversion of these dormant cells into cycling cells to target them afterwards with cytotoxic 
drug (Essers and Trumpp, 2010; Zeng et al., 2009).  
Therefore, it was studied whether LRC inherit permanent biological characteristics or whether 
they might represent a reversible functional phenotype. As dormancy was the main feature 
defining LRC, experiments were performed to study whether dormancy of LRC was a cell 
inherent, cell autonomous characteristic. 
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To address these questions, LRC and non-LRC of AML-491, AML-393 and ALL-199 were 
isolated from mouse bone marrow and sorted into LRC and non-LRC as described above and 
thereby dissociated from their environment; LRC and non-LRC were separately re-transplanted 
into secondary recipient mice (Figure 31). 
 
 
Figure 31 Experimental procedure for isolation and re-transplantation of LRC and non-LRC 
From a 1st recipient mouse carrying CFSE stained ALL-199 cells, LRC, non-LRC and bulk cells were obtained at 
day 10; bulk cells and non-LRC were re-labeled with CFSE, re-transplanted into secondary recipient mice at high 
numbers and re-analyzed at day 10 using flow cytometry; bulk cells, LRC and non-LRC were re-transplanted at 
low numbers into groups of mice and leukemia growth was monitored over time. 
 
A first readout was determining the distribution between LRC and non-LRC in second recipient 
mice. For this readout, second recipient mice were transplanted with 10 million cells of either 
the bulk mixture of all cells or non-LRC and analysis performed at day 10 by flow cytometry. 
As this approach required transplantation of high cell numbers, it was unfeasible performing it 
with LRC, as only low numbers of LRC can be recovered from each mouse. The distribution 
between LRC and non-LRC was highly similar, if not identical for the bulk mixture of all cells 
or non-LRC and both populations displayed a clear subpopulation of LRC (Figure 32A). Thus, 
upon re-transplantation of a populations exclusively containing non-LRC, LRC were derived 
in next recipient mice. These data suggest that fast proliferating non-LRC retain the capacity to 
convert into dormant LRC.  
To test the opposite question whether slowly proliferating LRC might be able to convert into 
fast proliferating non-LRC, a second readout was used which used low cell numbers and could 
be applied to all three populations, namely the bulk mixture of all cells, LRC and non-LRC. 
When low cell numbers of either LRC, non-LRC or bulk cells were re-transplanted into next 
recipient mice, all populations initiated leukemic growth at identical speed in mice as monitored 
by in vivo imaging. For AML-491 after 13 weeks all three populations showed leukemic loads 
of around 1x1010 lg photons/s. The leukemic load of one mouse, transplanted with LRC had a 
delayed tumor growth, but also reached the same leukemic load. Probably, due to cell losses 
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during the complex isolation and injection procedure, fewer LRC cells were injected and 
engrafted and needed more time to induce the full leukemia. 
 
Figure 32: Release from the environment induces proliferation in AML LRC  
From a 1st recipient mouse carrying CFSE stained AML-491 or AML-393 cells, LRC, non-LRC and bulk cells 
were obtained at day 10 (AML-393) or at day 15 (AML-491). 
A Bulk cells and non-LRC were re-labeled with CFSE, re-transplanted in secondary recipient mice at high numbers 
and CFSE staining was re-analyzed at day 10 or day 15 using flow cytometry. 
B Growth curve in secondary recipients; bulk cells, LRC and non-LRC were re-transplanted at low numbers into 
groups of mice and leukemia growth was monitored over time by in vivo imaging. For ALL-199 no statistical 
significance was found between the linear regression slopes by Kruskal-Wallis test and Dunn’s multiple 
comparison tests. 
 
For AML-393 and ALL-199 all three population needed 6 or 8 weeks to show leukemic loads 
of 5x109 or 1x1011 lg photons/s, respectively (Figure 32B). The data show that re-
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transplantation into secondary recipient mice converted dormant LRC into fast proliferating 
cells. 
 
Thus, slowly proliferating LRC can give rise to fast proliferating cells upon re-transplantation 
and convert into non-LRC and vice versa; fast proliferating non-LRC can give rise to dormant 
LRC in the next generation of mice. These results suggest that LRC and non-LRC represent a 
reversible functional phenotype. AL cells exhibit a major functional plasticity and respond on 
the environmental context they are in. Therefore LRC might be targetable, by dissociating them 
from their environmental context and thereby converting them into treatable proliferating cells. 
 
The data showed in a PDX AL model the isolation and functional characterization of dormant 
cells which might be a surrogate for relapse-inducing cells in patients. This dormant and drug 
resistant stem cell subpopulation can be converted to proliferating cells by releasing them from 
their microenvironment. The developed model and the consequent findings will be of 
translational importance as they establish a basis to develop new treatment strategies to 
eradicate relapse-inducing cells in AL patients. 
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6 Discussion 
Acute leukemias (AL) consist of heterogeneous cell populations and the subgroup which 
displays treatment resistance determines the patients’ prognosis. Most AL patients initially 
respond to anti-leukemia therapy, but the majority of acute myeloid leukemia (AML) and 40-
50 % of acute lymphoblastic leukemia (ALL) patients develop disease relapse which is 
associated with poor outcome. Minimal residual disease (MRD) cells are a reason for relapse, 
as these cells survived chemotherapy and might persist even after prolonged time of therapy 
(Gokbuget et al., 2012b; Locatelli et al., 2013; Lokody, 2014; Patel et al., 2013). 
Novel treatment options are urgently needed to eradicate residual, treatment resistant cells, 
which have stem cell potential and therefore are able to induce relapse, to finally improve the 
cure rate and prognosis of patients with acute leukemia. For this a deep understanding is 
required on mechanisms determining treatment-resistance in vivo and the ability to induce 
relapse. Before this study, no functional studies on isolated MRD cells were performed as 
technical limitations like the reliable differentiation of malignant and healthy cells and the 
enrichment and isolation of very minute numbers of malignant cells hampered these studies so 
far. As treatment resistant cells are challenging to isolate, but considered to be dormant 
(Aguirre-Ghiso, 2007; Essers and Trumpp, 2010; Schillert et al., 2013), in this study dormancy 
was used as benchmark in searching for a therapeutically relevant subpopulation of AL cells. 
In this work, a preclinical mouse model was further optimized, which allowed the identification, 
isolation and enrichment of a rare subpopulation of in vivo long-term dormant cells in the PDX 
model of ALL and AML. Dormant cells were identified by label retaining cells (LRC) of the 
fluorescence dye 5-(6)-Carboxyfluorescein-Succinimidyl Ester (CFSE). The characterization 
of these LRC showed that they combine the three major adverse characteristics that challenge 
to cure cancer, namely (i) dormancy, (ii) in vivo drug resistance, and (iii) leukemia-initiating 
potential. In conclusion, LRC represent a preclinical surrogate for treatment resistant, dormant, 
and relapse-inducing cells in acute leukemias. Therefore, PDX LRC cells represent a valuable 
tool to investigate mechanisms of resistance, dormancy, and relapse in patients. The new 
insights, which could be gained with help of this model, might finally lead to the development 
of novel therapies to eliminate treatment resistant cells, prevent disease relapse and increase the 
prognosis of patients with ALL. 
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6.1 Isolation of minute numbers of PDX cells enables studies on 
non-dividing AL cells 
The basis for this study was the NSG PDX model of acute leukemias. This model is an attractive 
possibility to experimentally study patients' tumor cells in vivo, which uses immuno-
compromised mice to expand and study tumor cells from patients (Shultz et al., 2005; Terziyska 
et al., 2012; Vick et al., 2015). It circumvents the limitations of in vitro approaches as cell lines 
display altered proliferation behavior and gained additional mutations by their immortalization, 
departing them from the original patients’ leukemia (Pan et al., 2009). As cell lines do not have 
genetic or dormant subclones and all cells participate in proliferation, cell lines could not be 
used within this study to search for challenging subpopulations. In addition the number of 
available cancer cell lines is inadequate regarding the diversity of cancer subtypes (Gillet et al., 
2011; Hausser and Brenner, 2005). Also in vitro approaches with primary tumor cells have 
significant limitations as they are reluctant to proliferate in vitro and material is limited (Mitra 
et al., 2013). Nowadays, a large amount of different leukemia PDX models have been 
established (Lee et al., 2007; Liem et al., 2004; Townsend et al., 2016). The broad number of 
available xenografts can reflect the complexity of the disease regarding different subtypes of 
the disease, namely different precursor cells, different genetic alterations, diagnosis and relapse 
samples, pediatric and adult patients, with and without cytogenetic changes. Furthermore, 
studies within the bone marrow microenvironment are possible (Townsend et al., 2016). As 
shown previously, PDX AL cells retain important characteristics of primary AL cells and 
remain mainly stable after successive passaging in mice regarding important characteristics 
such as time to overt leukemia, cell surface markers, response to drugs in vitro, and mutation 
pattern (Castro Alves et al., 2012; Lock et al., 2002; Rosfjord et al., 2014; Schmitz et al., 2011; 
Terziyska et al., 2012; Townsend et al., 2016; Vick et al., 2015). PDX models are mostly used 
for preclinical treatment trials (Gao et al., 2015; Suryani et al., 2014; Townsend et al., 2016). 
Here the model was developed further to isolate, enrich and characterize minimal numbers of 
AL cells from mice, based on transgenic expression of artificial molecular markers. 
Genomically integrated molecular tags were used to reliably and stably mark the PDX cells. 
Lentiviral integration into the genome of xenograft cells could possibly alter their properties, 
as the vectors might lead to clonal imbalance, and malignant cell transformation due to 
integration and upregulation of proto-oncogenes (Modlich et al., 2009). However, until now, 
no alterations in functional behavior of PDX cells before and after genetic engineering, that 
could have been caused by lentiviral transduction and the EF-1α as non-viral promoter, have 
Discussion  82 
 
 
 
been detected (Barrett et al., 2011; Bomken et al., 2013; Iacobucci et al., 2016; Terziyska et al., 
2012; Vick et al., 2015). The advantage of the molecular approach with artificial molecular 
markers lies in the unbiased isolation of PDX cells independently from endogenous surface 
antigens, which might be restricted to leukemia subpopulations. For example, in BCP-ALL it 
has been shown that previous CD19 expressing ALL cells can develop a CD19 negative relapse 
(Maude et al., 2015). Meaning that here the use of the endogenous marker CD19 for the 
identification of ALL cells would fail to identify the cells responsible for the relapse.  
The optimized and developed methods enabled the enrichment and isolation of transgenic PDX 
cells at early time points and low cell numbers. In patients, AL is frequently detected at 
advanced stages of the disease, when disease symptoms, like bleeding and infections, appear 
and bone marrow already contains in average between 30 % and 80 %, sometimes even more, 
malignant cells (De Kouchkovsky and Abdul-Hay, 2016). Most patients receive anti-leukemia 
treatment directly after diagnosis. Without treatment, patients die within few months due to 
bone marrow failure (De Kouchkovsky and Abdul-Hay, 2016; Estey and Dohner, 2006; Pui 
and Evans, 2013). But as a consequence, little is known about the growth of leukemia in 
patients. Investigations on leukemia biology were performed at diagnosis, meaning at late time 
points of the disease, during treatment process or at relapse (De Kouchkovsky and Abdul-Hay, 
2016; Pui et al., 2015). Investigations on early leukemia development are missing. Due to 
technical limitations even in vivo models concentrate on late time points, when a large amount 
of leukemic cells can easily be isolated and studied. Suitable models and techniques are urgently 
needed to study engraftment and investigations on early leukemic development (Barrett et al., 
2011). So far, the same technical obstacles hampered characterizing phenotypic and functional 
features of relapse-inducing cells in leukemia patients in detail. These cells are difficult to 
clearly identify, and only exist at low numbers, hampering their isolation and availability for 
further experiments or characterization. Whereas the present study enables for the first time 
isolation of low numbers of pure leukemic cells and therefore investigations on early leukemia 
growth. 
Sebastian Tiedt started the study with the two high risk relapse samples ALL-199 and ALL-265. 
By CFSE labeling he identified in vivo long-term resting cells in these two samples. Without 
technical or biological replicates he showed that the long-term resting cells are treatment 
resistant (Tiedt, 2014). To exclude that only relapse samples show the identified dormant and 
drug resistant phenotype, a broader representative pool was chosen for this study. Relapse 
samples have already been exposed to chemotherapy, and might therefore represent a selected 
subset of particularly restive cells from the primary tumor. This might be a reason why they are 
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highly aggressive and grow best with short passaging times in mice compared to initial 
diagnosis samples (Meyer et al., 2011). In total, eight different AML and eight different ALL 
PDX samples were analyzed for the presence of a dormant subpopulation. To cover a high 
heterogeneity, the selected samples include different mutations, differences in cytogenetics and 
age, and samples were obtained from patients at initial diagnosis or from patients suffering from 
1st or 2nd relapse. Furthermore, these PDX samples have different passaging times between 30 
and 130 days. As all but one sample analyzed contained a long-term dormant subpopulation in 
vivo, it is concluded that the findings obtained in this study reflects a phenotype that is not 
restricted to single AL samples, but is rather a prerequisite of almost all AL samples. 
For the study two enrichment methods were used. The one based on NGFR MACS was 
optimized and the one based on mouse cell depletion (MCD) MACS was established.  
For the total study the optimization of the NGFR MACS lead to material savings and thereby 
to an enormous amount of cost reduction, while the experiments could still be reliably 
performed. 
The advantage of this new enrichment method based on MCD MACS is the independence of 
the second lentiviral construct containing the NGFR. Validation of this method showed the 
reliable isolation of few PDX cells from mouse bone marrow with only minor false positive 
events. Comparing both enrichment methods showed that both reliably identify and isolate 
identical small numbers of PDX cells from mouse bone marrow. Thus, both methods are 
adequate for the present study. 
In this study, two protocols were established, compared, and quality controlled to isolate, 
identify, and enrich minute numbers of PDX cells from mouse bone marrow with high 
reliability, sensitivity, and purity. 
6.2 Interaction between different AL samples and mouse bone marrow 
depends on sample specific characteristics 
The here developed enrichment methods enable the direct quantification of homed AL PDX 
cells to mouse bone marrow. The established models circumvent the former technical 
limitations of the identification, isolation, and enrichment of minute numbers of cells and 
enables thereby for the first time especially new insights into leukemia biology at early time 
points with direct cell number quantifications. Already Barrett and colleagues claimed that 
suitable models and techniques are urgently needed to study engraftment and investigations on 
early leukemic development. As different ALL samples show different kinetics in xenograft 
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models, detection and quantification of treatment effects in these models at early disease time 
points are interesting for new treatment options or the determination of patients’ outcome 
(Barrett et al., 2011). To investigate engraftment capacities of AL samples to mouse bone 
marrow, the gold standard method are limiting dilution transplantations assays (LDTA). They 
are used to compare differences of leukemia initiating cell (LIC) frequencies between different 
AML samples, between subpopulations regarding surface markers (Eppert et al., 2011; Sarry et 
al., 2011) and between treated and untreated samples (Castro Alves et al., 2012). The read-out 
is a qualitative one; the engraftment or the non-engraftment of cells in immunodeficient mice. 
The rates of positive and negative response at different doses allow the quantitative calculation 
of the LIC frequency with help of the ELDA software (Hu and Smyth, 2009). In addition the 
current standard method to detect engraftment of leukemia is the measurement of leukemia cells 
in the blood and most mice were only evaluated during endpoint analyzes. But these current 
methods do not give full insights into early leukemia growth, leukemia development or 
treatment response (Barrett et al., 2011), whereas the developed enrichment methods in this 
study now give the opportunity to study and quantify the early engraftment of AL. 
For engraftment studies, 107 PDX cells of eight ALL samples and of eleven AML samples were 
injected into mice and quantified from mouse bone marrow two or three days later. The homing 
capacity of the different PDX samples differed by more than two orders of magnitude. The 
maximum efficiency was around 4 % of injected cells that could be redetected after isolation, 
whereas the minimum efficiency was 0.01 % of the injected PDX cells.  
In addition, for the sample ALL-199, different cell numbers between 107 and 105 PDX cells 
were injected into mice and quantified from mouse bone marrow three days later. When higher 
cell numbers were injected, homing efficiency increased to a maximum of 1.2 %, whereas the 
injection of the lowest cell number only lead to a homing efficiency of 0.03 %. This shows that 
different PDX AL samples seem to have different engraftment rates to mouse bone marrow and 
the homing capacity depends on the cell number injected. The heterogeneity of homing capacity 
of different samples and different cell numbers are in line with previously published data, which 
show that AML or ALL PDX engraftment is a selective event, and that engraftment efficiency 
and time to full blown leukemia varies between different samples (Liem et al., 2004; Lock et 
al., 2002; Notta et al., 2011; Samuels et al., 2010; Sanchez et al., 2009). The current literature 
mainly concludes that different samples or different subpopulations might contain different 
frequencies of LIC.  
Later on in the study, qualitative LDTAs were performed for AML-393 and AML-491. Here 
LIC frequencies between 1/130 and 1/1400 were calculated. The data is in line with the direct 
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quantitative analysis of homed cells after three days for ALL-393 and AML-491, as here 0.3 
and 1 % of 107 injected cells homed to the mouse bone marrow.  
In contrast for ALL-199, qualitative analysis by LDTA showed 50 % engraftment for the group 
of 10 cells in the mouse bone marrow. Considering cell loss during the complex procedure of 
cell preparation and injection, these data suggest that each and every cell in this sample contains 
stem cell properties (Ebinger et al., 2016; Tiedt, 2014). In addition, other studies showed that 
in ALL almost every cell is a LIC, as LIC frequencies are very high (Morisot et al., 2010; Rehe 
et al., 2013). But in the present study, it seems that the engraftment rate drops if lower cell 
numbers are injected. A possible reason is the competition of transplanted cells with host bone 
marrow cells. Colvin and colleagues showed that transplanted cells and cells of the host bone 
marrow are in direct competition and the engraftment is directly related to the ratio of injected 
cells and bone marrow cells (Colvin et al., 2004). A reason for the high LIC frequency 
determined by LDTA might be the long-term evaluation. Here even very small cell numbers 
have time to increase to visible population. At early time points the present model might fail to 
quantify these few cells and might underestimated very small numbers. Further studies are 
necessary to explain on the one hand the decrease of homing efficiency for smaller cell 
numbers, but on the other hand the engraftment of very small cell numbers in ALL and AML 
at late time points as shown by LDTA.  
To calculate doubling times of eight different AML PDX samples, 107 PDX cells were injected 
into at least three different mice, and absolute numbers of PDX cells in the mouse bone marrow 
were quantified at different time points. From these numbers doubling times were calculated. 
The doubling times between the different AML PDX growing in mice differ broadly. The 
fastest sample has a doubling time of 1 day whereas the slowest sample has a doubling time of 
nearly 4 days. These different doubling times can explain the differences in passaging time of 
PDX AML and ALL samples in our group and in published data (Lock et al., 2002; Notta et 
al., 2011; Sanchez et al., 2009; Vick et al., 2015), as low doubling times lead to a faster increase 
of PDX cells and therefore to an earlier advanced leukemia burden in the mouse.  
Interestingly, the majority of cells that were injected in the present study are not able to home 
to the mouse bone marrow, as only minor fractions of injected cells were detected. A possible 
reason might be the homing of these cells to other organs than the bone marrow, which were 
not analyzed within this study. Other studies showed an early engraftment of leukemic cells to 
the liver (Barrett et al., 2011) and cells that home to the liver very early but left the liver again 
(Vick et al., 2015). But the early engraftment of the liver seems to be sample dependent as other 
studies showed a later engraftment of PDX within the liver (Bomken et al., 2013), whereas all 
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studies showed an obvious first engraftment to the bone marrow of the lower extremities. Thus, 
the bone marrow is the most important organ to investigate for engraftment rates. Furthermore, 
in this study around 75 % of the mouse bone marrow was analyzed (Colvin et al., 2004). It 
might be that the remaining bone marrow of thoracic limbs, skull or rib cage harbor more PDX 
cells. But it has been show that mainly the bone marrow of the lower extremities harbors 
leukemia cells at early time points (Barrett et al., 2011; Bomken et al., 2013) and therefore it 
seems to be very unlikely that the remaining bone marrow contains all the missing PDX cells. 
In theory cells might still circulate in the bloodstream and will engraft later. But for normal 
hematopoiesis it has been shown that the engraftment of injected hematopoietic stem cells 
(HSC) is finished after 4 hours and afterward no additional cells are engrafting (Ellis et al., 
2011). It seems likely that the same is true for AL cells. As a consequence, most injected cells, 
including the LIC, might have died and were degraded. 
These data indicate that the engraftment of specific leukemic sample into mouse bone marrow 
depends on the cell number injected and on specific characteristics of the individual samples, 
like different cell distribution in the mouse, different cell dying, or additional homing to other 
niches than the bone marrow, which might not been seen with the present model. Until now, no 
data exists about the number of niches in the bone marrow (Nombela-Arrieta and Manz, 2017). 
The data argue against the presence of a preformed and fixed number of niche places present in 
the bone marrow of each NSG mouse, which are able to house PDX cells (Ugarte and Forsberg, 
2013). In contrast, depending on the characteristics of the sample and the cell number injected, 
the bone marrow of each mouse seems to be able to home a different number of human leukemic 
cells.  
In summary, it was shown that the established model enables insight into early leukemia bone 
marrow engraftment and that the engraftment depends on sample specific characteristics.  
6.3 AL PDX samples show a logistic growth in mice 
Besides insights into early engraftment of AL PDX, also investigations on AL PDX growth 
would help to understand the biology of the disease in more detail to finally improve or develop 
new treatment strategies. 
In the present study lentiviral transduction of AL PDX samples enables enrichment and 
quantification of minute numbers of PDX cells from mouse bone marrow for detailed kinetics. 
Quantitative and relative analysis of PDX cells in mouse bone marrow over time showed an 
exponential increase of leukemic load for all analyzed samples over around two third of the 
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time from injection to leukemia induced death of the mouse, and growth slowed down 
thereafter. Mathematically, the early growth of PDX cells in mice is logarithmic, but slows 
down if about 10 % of cells within the mouse bone marrow are of human origin. This results 
mathematically in an overall logistic growth, which is an indicator for non-optimal nutrient 
supply (Schacht, 1980). A reason for logistic growth is space restriction, which seems on the 
one hand unlikely because the slowdown already happens when only 10 % of cells where of 
human origin but on the other hand it is likely because the bone marrow is surrounded by solid 
bone marrow, which cannot expand. Insufficient supply of critical resources like nutrients and 
oxygen by the bone marrow environment might diminish the proliferation rate of the leukemia 
cells, and is known to be another reason for the logistic growth of solid tumors (Araujo and 
McElwain, 2004; Bru et al., 2003; Casciari et al., 1992; Vaidya and Alexandro, 1982). Another 
reason for logistic growth could be an increase of cell death at high densities (Schacht, 1980). 
As it is known that PDX cells are spreading to other organs at later time points and that even 
the mouse bone marrow has up to more than 90 % leukemic cells at advanced leukemic stages 
(Bomken et al., 2013; Castro Alves et al., 2012; Jones et al., 2017; Wang et al., 2017), the 
possible increased cell death rate has to be compensated by a very high proliferations rate (Labi 
and Erlacher, 2015). Further studies are required to decipher the mechanisms which slow down 
leukemia growth at these low phases of leukemic infiltration in bone marrow. 
6.4 Subpopulation of dormant cells as model for relapse-inducing cells in 
patients 
In the present study CFSE staining was established to follow up proliferation. CFSE has already 
been used as proliferation marker in lymphocytes (Lyons and Parish, 1994; Parish, 1999), 
mouse HSC (Takizawa et al., 2011), and xenografts of solid tumors (Moore et al., 2012). Within 
this study, CFSE staining was established for ALL and AML PDX cells. By double staining 
with the widely used proliferation marker BrdU (Kee et al., 2002; Nakamura et al., 1991; 
Ninomiya et al., 2007), and the correlation of CFSE loss versus increase in absolute cell 
numbers in the mouse bone marrow, the present study shows that CFSE can reliably be used as 
proliferation marker of PDX cells. To analyze BrdU incorporation into DNA, permeabilization 
of these cells is necessary, meaning that cells die during this method. An advantage of CFSE is 
the detection of the signal in living cells without permeabilization, meaning that living cells can 
be further functionally characterized, and be re-injected for further studies.  
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Using the established enrichment methods combined with CFSE labeling, the present study 
discovered that PDX AML and ALL cells growing in mice reveal heterogeneity regarding 
proliferation. 107 PDX cells of several AML and ALL samples were labeled with CFSE, 
injected into mice, and PDX cells were enriched from mouse bone marrow and analyzed for 
CFSE content at different time points. AML and ALL contain a rare subpopulation of label 
retaining cells (LRC) which barely divide, even if tumor mass proliferated substantially. LRC 
existed in all but one different tested types of AL samples, in pediatric and in adult AL samples, 
in different risk groups as they exist in relapse and initial diagnosis samples. However, one 
AML sample did not contain LRC, indicating that the presence of LRC is not a mere 
stochastical event. Furthermore, LRC are not an artefact induced by the genetic engineering of 
the samples, because they also exist in samples without any lentiviral transduction or transgene 
expression. 
Thus, for the majority of samples, a few cells did not participate in proliferation. Like in normal 
hematopoiesis (Trumpp et al., 2010), PDX AML and ALL harbor rare, long-term dormant cells. 
In addition dormant cells were identified in primary ALL samples by Ki-67 staining (Lutz et 
al., 2013). However, the present study provides for the first time a preclinical tool to study 
dormant human AML and ALL cells in vivo and describes that long-term resting cells exist in 
AML and ALL. This fact was unknown so far, as immunohistochemistry and flow cytometry 
of primary patients' samples only allow quantifying dormant cells as a snapshot at a given 
moment when cells e.g., lacking Ki-67 expression. But these methods fail to distinguish 
between short-term and long-term resting cells (Lutz et al., 2013). In contrast, LRC represent 
long-term resting cells which did not divide for up to 29 days explaining their minor abundance 
compared to primary samples. In the present model system, the LRC fraction constantly 
diminished over time; one reason for this might lay in the technical limitation that cells which 
proliferate first and become dormant later lost their CFSE label, and thereby the present method 
might underestimate the frequency of resting cells. 
Development of relapse is a complex process involving genetic and non-genetic factors (Inaba 
et al., 2013). In adult ALL patients pre-existing minor clones with mutations responsible for 
drug resistance might lead to early relapse. Relapse originates often from treatment resistant 
cells that persist at MRD in the patients (Pui et al., 2008). Genome sequencing of matched 
diagnosis and relapse samples reveal that relapse samples often harbor specific genetic 
alterations. These genetic alterations were either acquired at relapse or already exist as minor 
clone at diagnosis and are responsible for the growth advantage and/or the treatment resistance 
of the subclone (Ding et al., 2012; Inaba et al., 2013; Pui et al., 2012). But some ALL cases are 
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genetically very stable, suggesting that here relapses are not mediated by mutational 
mechanisms (Staal et al., 2010). As cells at late relapse, meaning later than 30 month of 
diagnosis, often respond to the same treatment regimens as the cells at initial diagnosis, long-
term dormant leukemic cells without any additional mutation might be responsible for the 
relapse. Therefore ALL LRC might represent surrogates for cells responsible for late relapse 
and for relapse cells without any additional mutations, as often seen in children (Staal et al., 
2010). 
The fact that LRC exist might explain why patients suffering from leukemia profit from 
maintenance therapy. ALL patients are routinely treated with oral low dose chemotherapy from 
end of intensive chemotherapy until, e.g., 2 years after diagnosis, and maintenance therapy 
improves patients' prognosis (Schrappe et al., 2000). Low dose maintenance therapy might act 
by removing long-term resting leukemia cells with relapse-inducing potential when they start 
to proliferate. 
In conclusion the developed PDX model represents a unique tool to study long-term resting 
human leukemia cells in vivo and provides inside into leukemia biology. With the model, a rare 
dormant subpopulation within PDX AL cells was identified which might be a surrogate for 
relapse-inducing cells in patients. Therefore the developed model might be used as convenient 
tool to investigate new treatment strategies against dormant and relapse-inducing cells in 
patients. This tool enables for the first time improved research very close to the patients. 
6.5 Stemness and dormancy are not directly connected in AML 
A cancer stem cell (CSC) hierarchy has been described in numerous tumor entities including 
solid tumors (Visvader and Lindeman, 2008) and AML (Bonnet and Dick, 1997). Leukemia 
stem cells (LSC) are recognized as a clinically highly relevant subgroup of cells and are 
characterized by specific features such as self-renewal and dormancy (Essers and Trumpp, 
2010; Ishikawa et al., 2007; Viale et al., 2009). The identified LRC within this study are defined 
by their reduced proliferation rate. Additionally, Erbey Özdemir, a colleague in the hosting 
laboratory, showed that LRC are localized mainly within the endosteal bone marrow niche, 
which was defined as the region around the bone matrix with a distance of less than 100 µm to 
the closest bone matrix (Ebinger et al., 2016; Özdemir, 2017). The endosteal bone marrow niche 
was originally identified as the location of hematopoietic stem cells (HSC) and it has been 
shown that HSC rarely proliferate (Malhotra and Kincade, 2009; Trumpp et al., 2010). The 
same has been shown for CSC (Ishikawa et al., 2007). Therefore, it was studied whether AML 
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LRC are surrogates for LSC and whether AML stem cells can be enriched by the dormant 
phenotype. 
As surrogates for the LSC frequency, the leukemia initiating cell (LIC) frequency was 
determined by using the gold standard method LDTA (Castro Alves et al., 2012; Dick and 
Lapidot, 2005; Eppert et al., 2011; Sarry et al., 2011). In this study, the LIC frequency of sorted 
LRC and non-LRC in two different samples was compared. Sorted LRC and non-LRC were 
injected at different cell numbers into groups of mice and the engraftment of these cells was 
followed by blood measurement and in vivo imaging. From engraftment rates LIC frequencies 
was calculated using the ELDA software. Unexpectedly, CSC frequency was not higher in the 
LRC population; as LRC and non-LRC populations showed highly similar calculated LIC 
frequencies. These results are consistent with data of ALL LRC, as in ALL also LRC and non-
LRC have similar LIC frequencies (Ebinger et al., 2016; Tiedt, 2014). But the literature showed 
that LSC are mainly dormant (Ishikawa et al., 2007; Viale et al., 2009) and that only LSC can 
induce new tumors and propagate the disease (Bonnet and Dick, 1997; Huntly and Gilliland, 
2005; Lapidot et al., 1994; Reya et al., 2001). The current study showed that even fast 
proliferating leukemia cells have stem cell properties and can induce new tumors and that 
dormancy might not be an intrinsic characteristic of the here detected LRC, as pure LRC 
populations start to proliferate and induce new tumors. But the sample size within this study is 
very low and LRC and non-LRC were taken from their environment and re-injected into new 
mice for the LDTA. There might be putative extrinsic factors, that are responsible for the 
differences between LRC and non-LRC, but which are lost if they are taken from their former 
environment and placed into a new environment. 
The presented results that LSC exist in different phenotypic cell types are in line with current 
data about the heterogeneity of LSC. In contrast to the former theory that AML stem cells 
always express the markers lin-CD34+CD38-, and only these cells are able to induce a leukemia 
(Bonnet and Dick, 1997; Lapidot et al., 1994), present data shows that LSC are phenotypically 
heterogeneous (Eppert et al., 2011; Goardon et al., 2011; Jamieson et al., 2004; Sarry et al., 
2011; Taussig et al., 2010).  
Thus, as LRC and non-LRC have the same leukemia initiating potential, but different 
proliferation behavior in vivo, stemness and dormancy seems not to be directly connected in 
AML.  
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6.6 Drug resistance of LRC might be a consequence of their dormancy and 
bone marrow localization 
Tumor cells often display two challenging features, namely dormancy and drug resistance. 
Dormant cells are known for their resistance against cytotoxic drugs, complicating elimination 
by anti-cancer therapy (Essers and Trumpp, 2010). However, it is unclear whether either 
dormancy or drug resistance is pivotal in respect to the other, so that dormancy is a consequence 
of resistance or vice versa (Blatter and Rottenberg, 2015).  
As the identified LRC are defined by their dormant nature, the drug response of the dormant 
LRC and the fast proliferating non-LRC was compared. For this purpose as clinically related 
model, systemic in vivo drug treatment trials were performed. 107 CFSE labeled PDX cells were 
injected into mice. After seven days mice were treated with chemotherapy, followed by PDX 
cell enrichment and analysis for CFSE content 3 days later. LRC show marked resistance 
against in vivo chemotherapy. While systemic chemotherapy in mice reduced overall tumor 
mass by 90 %, most LRC survived chemotherapy. The relative drug reduction showed that 
proliferating cells were 10 to 100 fold more efficiently eliminated by in vivo chemotherapy than 
LRC. As a consequence, the relative percentage of LRC within the total population of cells 
isolated from treated mice increased significantly during treatment. LRC displayed in vivo 
resistance against a variety of different drugs of current ALL chemotherapy protocols used 
either in front line or in relapse. The study shows that acute leukemias consists of functionally 
heterogeneous cells regarding proliferation rate and drug resistance similar to functional 
heterogeneity shown in other tumor entities (Kreso et al., 2013). As LRC did not substantially 
participate in proliferation during growth of leukemia over weeks, and in treatment experiments 
over 10 days, LRC existed before onset of therapy and were not developed as a consequence of 
treatment. Drug resistance is associated with stem cell features of cancer cells (Wang, 2007). 
But as both LRC and non-LRC contain similar amounts of leukemia stem cells (LSC), but show 
different sensitivity towards drug treatment in vivo, the data implicate that stemness and drug 
resistance are not directly connected in acute leukemias. This assumption is supported by 
another current study, where it has been shown that cytarabine treatment resistant AML cells 
are not enriched for leukemia stem cells in an AML PDX model (Farge et al., 2017). 
In one AML sample, AML-491, also the LRC were largely reduced by the treatment. The 
reduction by the treatment was little less for LRC compared to proliferating cells, but the AML-
491 LRC did not show major drug resistance compared to the LRC of the other samples. In in 
vivo treatment trials with six different AML samples of a colleague in the hosting laboratory, 
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Binje Vick, only AML-491 was highly sensitive towards cytarabine treatment. Even one mouse 
was cured completely after treatment. The reason for this sensitivity might be that in this sample 
also the LRC are sensitive towards treatment. It shows that treating LRC might have a direct 
effect on the survival of mice. The data suggests that patients might benefit from treatment 
which targets dormant and drug resistant subpopulation. But the sample size with only one 
sample is very low and further samples which show LRC sensitivity would be needed to prove 
the correlation and to investigate the reasons for the drug sensitivity of these samples. 
Leukemia initiating cells are thought to be located in the hematopoietic niche where they 
interact with the environment, which might protect them from chemotherapy (Lane et al., 2009; 
Tabe and Konopleva, 2014). These cells might survive chemotherapy and could induce a new 
tumor. The results in this study are in line with this hypothesis, because the re-injection of drug 
resistant LRC into new recipient mice induced a new leukemia in those mice. Thus drug 
resistant LRC have stem cell properties. 
Furthermore, an interaction of LRC with the hematopoietic niche would explain their dormant 
phenotype, as a direct correlation between dormancy of HSC and their localization within the 
hematopoietic niche has been observed (Arai et al., 2004; Fleming et al., 2008; Wilson et al., 
2008). Moreover, even a drug resistance of HSC localized in the niche has been shown (Cheng 
et al., 2000). Indeed further studies of the hosting laboratory by Erbey Özdemir on the 
localization of LRC in the mouse bone marrow showed that LRC are significantly more located 
within the endosteal niche than non-LRC (Ebinger et al., 2016; Özdemir, 2017).  
As the identified LRC are drug resistant and are able to induce a new leukemia they might be 
surrogates for minimal residual disease (MRD) cells in patients; these cells survived drug 
treatment in patients and are often responsible for relapse. MRD levels are even a prognostic 
factor, as the level of MRD correlates with the risk for relapse (Gokbuget et al., 2012b; Locatelli 
et al., 2013; Paietta, 2015; Pettit et al., 2016).  
Taken together, LRC are characterized by a combination of three features that challenge anti-
leukemia treatment: dormancy, leukemia initiating potential and drug resistance, which might 
be a consequence of their bone marrow localization. As the established PDX model presented 
here covers all three features, this model might help to further characterize these cells and 
ultimately used to test new treatment regimens to increase outcome in patients and to prevent 
relapse.  
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6.7 The reversible phenotype of LRC might be a clinical treatment option 
One new treatment strategy against drug resistant cells might be to break their dormancy. For 
dormant HSC it has been shown that they can be modified by different factors to start 
proliferation. As a result the former drug resistant HSC were sensitized towards chemotherapy 
(Trumpp et al., 2010).  
Therefore, the question rises whether the detected subpopulation of LRC can be transformed to 
proliferating and thereby treatment sensitive cells. Regarding dormancy and proliferation the 
study investigated whether AL cells have a reversible or fixed phenotype. If LRC and non-LRC 
have a genuinely different biology harboring distinct and constant intrinsic characteristics, they 
might be organized in a hierarchical way similar to the known stem cell hierarchy existing in 
many tumors including AML (Kreso and Dick, 2014). If LRC and non-LRC have a temporary 
and reversible phenotype, they might behave like long-term dormant HSC. These cells can start 
cycling in response to stress for a defined period of time and turn back into dormancy later 
(Trumpp et al., 2010).  
In this study, re-transplantation experiments of dormant LRC showed that they started to 
proliferate when they were dissociated from their environment and injected into next recipient 
mice. When fast proliferating non-LRC were dissociated from their environment, re-labeled 
with CFSE and injected into next recipient mice, they gave rise to the same heterogeneous 
pattern as before, including dormant LRC. Thus, the study detected that dormant cells can 
convert into fast proliferating cells and vice versa. Therefore, this data favors the second 
scenario, as LRC and non-LRC exhibit their proliferation phenotypes as reversible, temporary, 
transient functional phenotypes. 
These new insights harbor direct translational consequences. As LRC lose their clinical relevant 
phenotype after release from the bone marrow environment, rapid sample processing might be 
critical for reliable profiling for diagnostics. But this is still a challenge in clinical routine 
(Bacher et al., 2010). 
The phenotypic reversibility detected in acute leukemias parallels to normal hematopoiesis, in 
which long-term dormant HSC start cycling in response to stress for a defined period of time 
and turn back into dormancy later (Essers et al., 2009; Wilson et al., 2008). For HSC it has even 
been shown that breaking their dormancy with different factors sensitized them towards 
chemotherapy (Essers et al., 2009; Trumpp et al., 2010). The data indicates that it also might 
be possible to convert dormant AL cells into proliferating cells by treating them with certain 
factors, and thereby converting the former drug resistant dormant cells into drug sensitive cells. 
Discussion  94 
 
 
 
And indeed for leukemia stem cells (LSC) it has been already shown that converting LSC from 
a dormant state into proliferation can efficiently sensitize them towards chemotherapy (Essers 
and Trumpp, 2010). In AML, treatment efficacy was enhanced in vitro and in vivo by converting 
dormant AML cells into proliferation (Kuhne et al., 2013; Nervi et al., 2009; Saito et al., 2010b; 
Zeng et al., 2009). In ALL, similar therapeutic strategies were efficient (Parameswaran et al., 
2011; Sison et al., 2013; Welschinger et al., 2013). 
In addition this study showed that AL cells sustain major biological plasticity for adapting to 
the current situation and on external stimuli. Putative extrinsic factors influencing AL 
proliferation rates might result from the direct in vivo environment. As this study was restricted 
to bone marrow and the identified LRC are localized within a certain bone marrow 
microenvironment, the endosteal bone marrow niche (Ebinger et al., 2016; Özdemir, 2017), the 
bone marrow niche might play an important role in determining proliferation rate in this study. 
Already in healthy hematopoiesis, it has been shown that dormant HSC are located in the 
endosteal bone marrow niche (Wilson et al., 2007). Within this bone marrow niche, different 
cellular compartments and the molecular crosstalk by secreted factors regulate the maintenance 
of HSC in the niche (Kiel and Morrison, 2008; Wilson and Trumpp, 2006). In addition in 
leukemia increasing evidence exists regarding the close interplay between the bone marrow 
niche and leukemia cells residing therein, and mechanisms by which the niche supports the 
leukemic disease start to become unraveled (Raaijmakers, 2011). For ALL, it has been shown, 
that these cells are located in special bone marrow niches (Pitt et al., 2015) and that leukemic 
cells within the niche are quiescent (Saito et al., 2010b). Therefore, LRC might be dormant 
because of their localization close to the endosteal bone marrow niche. This is supported by the 
fact that LRC start to proliferate when they were dissociated from their environment. 
Disrupting this leukemia-niche interaction might represent an interesting concept for future 
therapies (Tabe and Konopleva, 2014). If treatment can release LRC from their in vivo 
environment, LRC might start to proliferate and thereby become sensitive towards 
chemotherapy. In normal hematopoiesis the interaction between HSC and their 
microenvironment can be disturbed to mobilize HSC (Morrison et al., 1997; Rettig et al., 2012). 
But also in AML, a treatment option is to induce mobilization of AML cells, to get them into 
circulation, which then enhances treatment effects of chemotherapy (Kuhne et al., 2013; Nervi 
et al., 2009; Zeng et al., 2009). In addition, targeting the niche in ALL, by disturbing the 
signaling between CXCL12 and its receptor CXCR4, leads to decreased development of 
leukemia (Pitt et al., 2015). The cytokine CXCL12 is produced by stromal cells and known to 
be important for the localization and maintenance of HSC (Lane et al., 2009).  
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As the current study showed that the dormant state of LRC is not an intrinsic but rather a 
convertible, temporary characteristic, also drug resistance might be a transient characteristic of 
LRC. In addition localization of LRC to the bone marrow niche seems to influence both, their 
dormancy and their drug resistance. These findings enable a first step towards new therapies. If 
dormant cells can be converted into proliferating cells, probably by targeting the bone marrow 
microenvironment, it should be able to target them afterwards with chemotherapy, reduce 
minimal residual disease and finally prevent relapse in patients.  
6.8 Outlook 
In this study, a dormant, drug resistant and stem cell like subpopulation within patient derived 
xenograft (PDX) acute leukemia (AL) cells was identified and characterized. It could be shown 
that this subpopulation is long-term resting, does not respond to chemotherapy-treatment in 
vivo, and is capable of inducing a new tumor (Figure 33). Therefore, these cells combine all 
adverse characteristics that challenge clinical success in AL patients (Lutz et al., 2013). As 
these cells might survive standard therapy and eventually lead to a relapse, they jeopardize 
patients’ prognosis.  
However, and as demonstrated in Figure 33, the rare population identified in this study has a 
reversible phenotype. When located on the endosteal bone marrow niche, which seems to have 
a protective influence, this subpopulation is dormant, drug resistant, and has leukemia stem cell 
properties. By release from the microenvironment, this population can be converted to a 
proliferating phenotype and might therefore be responsive towards therapy. This feature might 
therefore be a promising approach to target this adverse population. 
As demonstrated in further studies by Erbey Özdemir (Ebinger et al., 2016; Özdemir, 2017), 
the LRC population characterized here, resembles minimal residual disease (MRD) cells of AL 
patients. During the treatment of AL, treatment resistant cells represent a major challenge, as 
they eventually induce relapse which is associated with poor prognosis (Gokbuget et al., 2012b; 
Locatelli et al., 2013; Paietta, 2015; Pettit et al., 2016). To prevent relapse in patients it is 
important to eradicate treatment resistant, dormant tumor cells.  
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Figure 33: Plasticity hypotheses of human acute leukemic cells growing in mice.  
Newly identified rare acute leukemic cells are dormant, drug resistant, have stem cells properties and are localized 
in the endosteal niche whereas most acute leukemic cells are proliferating, are drug sensitive, have stem cell 
properties and are not localized in the endosteal niche. But cells do not have a fixed phenotype: depending on the 
microenvironment they can convert into one or the other phenotype.  
 
This plasticity of AL cells has a putative clinical relevance. For potential novel treatment 
strategies, the transient nature of the adverse characteristics of LRC suggests aiming at 
removing MRD cells from their protective environment in order to sensitize them towards 
chemotherapy treatment (Essers et al., 2009; Essers and Trumpp, 2010). The interaction 
between MRD cells and their bone marrow niche represents a promising target for novel 
therapeutic approaches to prevent relapse.  
More research is required to define the vulnerable targets of the LRC subpopulation or of the 
niche cells providing protection.  
Possible candidates for therapeutic targets are surface antigens that are differently expressed on 
LRC and non-LRC. Their inhibition on LRC might release these cells from their protective 
microenvironment. Beyond targeting the tumor cells, also the bone marrow microenvironment 
might be an effective target. Here signaling or surface molecules might be inhibited to shut 
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down environmental support. But as each non-LRC can convert into a drug resistant LRC, when 
it gets access to the protective niche, a persistent therapeutic inhibition might be required over 
prolonged periods of time. 
As the study showed that the microenvironment influences the functional phenotype of AL cells 
like dormancy and drug resistance, this data might explain the limited explanatory power of in 
vitro assays: Both constantly proliferating cell line cells and non-cycling, primary leukemia or 
PDX cells are highly sensitive towards chemotherapy in vitro, and can therefore not mimic 
drug-resistant MRD cells in the patient. Drugs that are effective in these in vitro assays often 
fail in patients (Kamb, 2005; Sun et al., 2006). One reason might be the missing influence of 
the microenvironment (Dhami et al., 2016; Pemovska et al., 2013; Wu et al., 2010). Recently, 
to improve drug testing in vitro, the bone marrow microenvironment is often included by using 
co-culture systems with human or mouse bone marrow stromal cells (Dhami et al., 2016; 
Frismantas et al., 2015; Pemovska et al., 2013; Suryani et al., 2014). However, as the critical 
factors responsible for the protective niche are not yet characterize, it is unclear if these methods 
are suitable model systems with predictive value. Furthermore, direct research on patients MRD 
cells is difficult due to their cryptic nature and minute number. This limits their isolation for 
further research (Hedley and Keeney, 2013; Ommen, 2016). PDX models circumvent these 
limitations. PDX models of different tumor entities have been already successfully used for the 
prediction of clinical outcome, for preclinical drug development, for the identification of 
biomarkers and for personalized medicine strategies (Bertotti et al., 2011; Dong et al., 2010; 
Gao et al., 2015; Garrido-Laguna et al., 2010; Hidalgo et al., 2011; Keysar et al., 2013; Liem et 
al., 2004; Rajeshkumar et al., 2009). In addition, in personalized treatment PDX have been 
already successfully used for new treatment strategies (Trahair et al., 2016). 
LRC in the here presented PDX model can repetitively be studied as highly enriched, pure 
fraction following the established isolation and enrichment protocol. The model allows the 
repetitive work on pure vivid LRC and thereby allowed the functional and phenotypical 
characterization of the population, which would not have been possible with primary patients’ 
MRD cells. LRC might represent a preclinical surrogate for a clinically relevant subpopulation 
threatening AL patients. Furthermore, LRC in the acute leukemia PDX model will serve as 
informative tool for the development of novel treatment strategies aiming at preventing AL 
relapse. Therefore LRC in the here developed preclinical model can now be used as surrogates 
for relapse-inducing cell, for developing novel therapies in order to prevent relapse and increase 
the prognosis of AL patients. 
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